



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 050 541 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
08.11.2000 Bulletin 2000/45(51) Int. Cl.<sup>7</sup>: C07K 14/44, A61K 39/018,  
C12N 15/00, C07K 16/20,  
G01N 33/53

(21) Application number: 00201485.0

(22) Date of filing: 25.04.2000

(84) Designated Contracting States:  
 AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
 MC NL PT SE  
 Designated Extension States:  
 AL LT LV MK RO SI

(30) Priority: 29.04.1999 EP 99201322

(83) Declaration under Rule 28(4) EPC (expert solution)

(71) Applicant: Akzo Nobel N.V.  
6824 BM Arnhem (NL)

(72) Inventors:  
 • Schetters, Theodorus Petrus Maria  
 5432 CD Cuyk (NL)

- Carcy, Bernard  
34070 Montpellier (FR)
- Gorenflo, André  
34090 Montpellier (FR)
- Précigout, Eric  
34730 Prades Le Lez (FR)
- Vallet, Alexina  
St. Paul en Chablais (FR)

(74) Representative:  
 Mestrom, Joannes Jozef Louis et al  
 N.V. Organon,  
 Postbus 20  
 5340 BH Oss (NL)

## (54) Babesia vaccine

(57) The present invention relates to the nucleic acid sequence of genes encoding proteins of the 37 kD protein family of *Babesia divergens*. Furthermore, the invention relates to recombinant molecules comprising such nucleic acid sequences, live recombinant carriers comprising such nucleic acid sequences and host cells comprising such nucleic acid sequences. Yet another embodiment of the invention relates to vaccines against *Babesia divergens* comprising proteins of the 37 kD protein family, nucleic acid sequence of genes encoding proteins of the 37 kD protein family of *Babesia divergens*, recombinant molecules comprising such nucleic acid sequences, live recombinant carriers comprising such nucleic acid sequences, host cells comprising such nucleic acid sequences, antibodies against proteins of the 37 kD protein family and methods for the preparation of such vaccines. Additionally, diagnostic kits for the detection of *Babesia divergens*, diagnostic kits for the detection of antibodies against *Babesia divergens* and methods for the detection of *Babesia divergens* and antibodies against *Babesia divergens* are disclosed. Finally, an embodiment relates to the use of a protein of the 37 kD protein family or a mixture of such proteins for the manufacture of vaccines.

**Description**

**[0001]** The present invention relates to the nucleic acid sequence of genes encoding proteins of the 37 kD protein family of *Babesia divergens*, recombinant molecules comprising such nucleic acid sequences, live recombinant carriers

5 comprising such nucleic acid sequences, host cells comprising such nucleic acid sequences, vaccines against *Babesia divergens* comprising proteins of the 37 kD protein family, methods for the preparation of such vaccines, methods for the detection of antibodies against a protein of the 37 kD protein family, diagnostic kits for the detection of *Babesia divergens*, diagnostic kits for the detection of antibodies against *Babesia divergens* and methods for the detection of *Babesia divergens*.

10 **[0002]** The parasite *Babesia divergens* causes severe economical losses in cattle. The genus *Babesia* to which *Babesia divergens* belongs comprises amongst others also the species *B. bovis*, *B. canis* and *B. bigemina*. In Europe, *Babesia divergens* is the most pathogenic *Babesia* species affecting cattle. (Kuttler, K.L., in M. Ristic (ed.), Babesiosis of domestic animals and man. CRC Press, Inc., Boca Raton, Fla. 1988). The parasite is transmitted by the three-host cattle-tick *Ixodes ricinus*. *Babesia divergens* causes anaemia in cattle, in severe cases leading to death. The disease

15 is also called "red water" since in a progressed state it causes bloody urine. The problem of bovine Babesiosis has been a long-standing problem: vaccination against bovine Babesiosis in Sweden, using blood from carrier cattle which had acute Babesiosis in the previous summer, was already advised by local veterinary authorities in 1920. In spite of all efforts however, there is still no safe and efficacious vaccine commercially available today, although in Sweden alone, babesiosis costs farmers more than 875.000 \$ each year. It has been shown that babesiosis in cattle can be controlled

20 by vaccination with live attenuated vaccines. The presently available live vaccines however have the drawback that their application needs veterinary surveillance. This is due to their variable infectivity and morbidity: in unhealthy animals an attenuated live vaccine causes a virulent infection leading to sickness.

It is known that vaccination with live vaccines is however not necessary. It appeared that so-called Soluble Parasite Antigen (SPA) preparations are capable of inducing an immune response that, although not necessarily affecting the parasite, sufficiently reduces the level of clinical manifestations upon infection. (Rev.: Schetters et al. in Parasitology today 11: 456-462 (1995)).

Further analysis of the various components found in SPA has revealed several proteins that possibly play a role in inducing protection against infection, or at least against the clinical manifestations of the infection. When the SPA proteins were separated into 4 separate groups F1-F4, based on their molecular weight, it surprisingly turned out that all 4 groups contained a compound that gave at least a certain amount of protection against infection. (Précigout et al., Experimental Parasitology 77: 425-434 (1993)).

30 Of the proteins found in the F4-fraction, one specific *Babesia divergens* protein has been studied for several years already for its use in vaccines: the 17 kD Merozoite Membrane protein. Of this protein it has been strongly suggested that it plays a very important role, if not the key role, in inducing immunity against *Babesia*. This was based i.a. upon

35 the finding that monoclonal antibodies against the 17 kD protein were induced after live infection and could *in vitro* drastically inhibit growth of the parasite. (Précigout et al. (1993), Exp. Parasitol. 77 (4) : 425-34).

**[0003]** Two other proteins, present in the same fraction that comprises the 17 kD protein, i.e. the F4-fraction, and also recognised by antiserum against *Babesia divergens*, are a 50 kD protein and a 37 kD protein. (Carcy et al., Infect. and Immun. 63: 811-817 (1995)). The detection of both the 50 kD and the 37 kD protein was based on the fact that *in vivo*

40 antibodies are raised against these proteins. This is however the case with many proteins of the SPA: practically all proteins are capable of raising antibodies, but only one or a minor number of proteins plays a role in the induction of neutralising antibodies.

Only antibodies against the 17 kD protein were known to possess protective activity. Thus, one would expect this 17 kD protein to be the protein of the F4-group that is responsible for inducing immunity. And therefore the possible role of the other F4-proteins, e.g. the 37 kD and the 50 kD protein remained fully unclear.

**[0004]** It is an objective of the present invention to provide an novel and efficient vaccine component against *Babesia divergens* infection in cattle, or at least against the clinical manifestations of the infection.

**[0005]** In one embodiment, therefore, the present invention provides for the first time the nucleotide sequence of the gene encoding the 37 kD protein. Surprisingly it was found, that the 37 kD protein can be found in at least two different variant forms: a 37 kD form and a slightly shorter form; a 35 kD form. Other, slightly smaller or larger forms are also seen. The form depends on the *Babesia divergens* strain from which the gene was isolated. It is therefore appropriate to talk about a 37 kD protein family rather than merely a 37 kD protein. The reason for the difference in size of the various members lies in the fact that certain regions of the protein can apparently be deleted without drastically altering the function of the protein (see below). Many different *Babesia divergens* strains have until now been isolated

55 that indeed show such variations in molecular weight of the 37 kD protein. It will be clear, that the molecular weight of the proteins is determined on a PAGE-gel relative to marker proteins. Therefore it is appropriate to read 37 kD as 37 kD (+/- 3 kD), and to read 35 kD as 35 kD (+/- 3 kD).

It is clear that for the determination of the level of homology between two members of the 37 kD protein family, a DNA

fragment that is present in one protein and deleted in the other contributes to a decrease in homology level, even in the case that all nucleic acids still present would be 100 % homologous. The following may serve as an example: if the genes encoding a 37 kD protein and a 35 kD protein are compared, there is a non-homology of 5% which is only due to the deletion in the shorter of the two genes. Therefore, in order to compensate for those differences in homology that are due to differences in size of the proteins of the 37 kD protein family, the minimal level of overall homology between the genes encoding the various proteins of the 37 kD protein family is estimated to be 60%. Thus, the 37 kD protein family comprises those proteins of which the genes encoding them share at least 60% homology with the genes encoding the 37 kD protein family of which the nucleic acid sequences are given in SEQ ID NO: 1, 2 and 3. These sequences are merely given as examples of proteins of the 37 kD protein family. The algorithm used for the determination of the level of nucleic acid homology is known as "Clustal W" and has been described by Thompson et al., in Nucleic Acid Research 22: 4673-4680 (1994). The program can be found at several sites on Internet.

All genes encoding a protein of the 37 kD protein family that share at least 60% homology with the nucleic acid sequences given in SEQ ID NO: 1, 2 or 3 are considered to be members of the 37 kD protein family. For e.g. vaccine applications (see below) the homology between a selected gene encoding a protein of the 37 kD protein family and SEQ ID NO: 1, 2 or 3 will preferably be somewhat higher than 60%. Although a 60% homology with SEQ ID NO: 1, 2 or 3 would be acceptable, a homology of > 70 % would be preferred. A homology of > 80% is more preferred, whereas an homology of > 90% is most preferred.

In exceptional cases, a member of the 37 kD protein may be found to have a nucleic acid homology that is below the level given above. This may e.g. be caused by an exceptionally large deletion. Nevertheless, such genes belong to the family of genes encoding a protein of the 37 kD protein family if they hybridise with any of the genes of which the nucleic acid sequence is given in SEQ ID NO: 1, 2 or 3 under stringent conditions. The conditions for hybridisation are given in Example 1.

**[0006]** Another way of determining if a protein belongs to the proteins of the 37 kD protein family is based upon binding of the protein to a specific antibody. This way of characterising the proteins of the 37 kD family is provided below. The characterisation is based upon the specific reaction of proteins of the 37 kD protein family with the monoclonal antibody F4.2F8. This monoclonal antibody binds to most proteins of the 37 kD family tested so far. The monoclonal antibody is highly specific; a common characteristic of all monoclonal antibodies. A hybridoma cell line producing the monoclonal antibody F4.2F8 has been deposited with the European Collection of Cell Cultures (ECACC), Centre for Applied Microbiology & Research (CAMR), Salisbury, Wiltshire SP4 OJG United Kingdom, under accession number 99031816. Therefore, all proteins binding to F4.2F8 are considered to be members of the 37 kD protein family.

It can not be excluded that occasionally a strain is isolated having a protein of the 37 kD protein family that does not bind to monoclonal antibody F4.2F8. In such exceptional cases, the gene encoding the protein will however still hybridise to a gene of which the nucleic acid sequence is given in SEQ ID NO: 1, 2 or 3, or the gene will show a homology of at least 60 % with the nucleic acid sequence is given in SEQ ID NO: 1, 2 or 3.

**[0007]** In a first embodiment, the invention provides a nucleic acid sequence of *Babesia divergens* that encodes a protein of the 37 kD protein family or an immunogenic fragment thereof.

**[0008]** It could be shown by sequence analysis of the genes encoding the 37 kD protein family in the various strains, that the difference in size is often due to the presence, absence or polymorphism of small nucleic acid deletions in the gene. This is shown in fig. 1. This figure shows a sequence comparison between the *B. divergens* strains Rouen 1987 (R), Weybridge 8843 (W) and Y5. It can be seen that strains W and Y5 encode a 35 kD variant form, whereas strain R encodes a 37 kD variant.

**[0009]** Next to the presence/absence of the deletion in W and Y5 compared to R, there are minor variations in the overall nucleic acid sequence of the gene encoding a protein of the 37 kD protein family in the respective *Babesia* strains. These variations may have no effect on the amino acid sequence of the polypeptide, in case that the modification is such that the variant triplet codes for the same amino acid. This cause of variation is based upon the phenomenon of degeneracy of the genetic code. It happens e.g. that due to natural mutation the G in the triplet CTG, coding for the amino acid Leucine, is replaced by a C, also coding for Leucine, or that the G in GAG coding for glutamic acid is replaced by an A, which triplet still encodes glutamic acid. Such a mutation is a silent mutation, i.e. it does not show at the amino acid level. Such silent modifications are very frequently found in nature, when comparing e.g. two different field isolates of *Babesia divergens*. This phenomenon holds for all amino acids, except Met and Trp. Thus, it is obvious, that the protein family of the present invention can not only be coded for by the nucleotide sequences given in SEQ ID NO: 1-3 but also by a very large variety of other sequences, all encoding the identical protein. It therefore goes without saying that any nucleic acid sequence encoding the proteins of SEQ. ID. NO: 1, 2 or 3 of the present invention as well as nucleic acid sequences having a 60% homology are also considered to fall within the scope of the invention.

**[0010]** It will be understood that, for the particular proteins embraced herein, natural variations can exist between individual *Babesia* parasites or strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions which do not essentially alter biological and immunological activities, have been

described, e.g. by Neurath et al in "The Proteins" Academic Press New York (1979). Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 227, 1435-1441, 1985) and determining the functional similarity between homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immunoreactivity. Thus, variations not essentially influencing the immunogenicity of the protein compared to the wild type protein as depicted in SEQ ID NO: 4-6 are considered to fall within the scope of the invention. Those variations in the amino acid sequence of a certain 37 kD protein according to the invention that still provide a protein capable of inducing protection against infection with *B. divergens* or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunogenicity".

5 [0011] In a preferred form, the invention relates to a nucleic acid sequence encoding a 37 kD protein or an immunogenic fragment thereof. Such a sequence could e.g. be isolated from an R strain, or any other strain encoding a protein of the 37 kD protein family with a molecular weight of 37 kD.

10 [0012] In a more preferred form of this embodiment the gene encoding the 37 kD protein has the sequence depicted in SEQ ID NO: 1.

15 [0013] In another preferred form, the invention relates to a nucleic acid sequence encoding a 35 kD protein or an immunogenic fragment thereof. This sequence could e.g. be isolated from a W strain, or any other strain encoding a protein of the 37 kD protein family with a molecular weight of 35 kD.

20 [0014] In a more preferred form of this embodiment the gene encoding the 35 kD protein has the sequence depicted in SEQ ID NO: 2 or 3.

25 [0015] The invention also relates to nucleic acid sequences encoding a protein of the 37 kD protein family that is capable of binding to the monoclonal antibody F42F8.

30 [0016] A definition of immunogenic fragments of a protein of the 37 kD protein family will be given below, where another embodiment of the invention, i.e. vaccination is discussed.

35 [0017] In general, the term "protein" refers to a molecular chain of amino acids with biological activity. A protein is not of a specific length and can, if required, be modified *in vivo* or *in vitro*, by, for example, glycosylation, amidation, carboxylation or phosphorylation; thus, inter alia, peptides, oligopeptides and polypeptides are included within the definition.

40 [0018] Since the present invention discloses the nucleic acid sequence encoding members of the 37 kD protein family, it is now for the first time possible to obtain such proteins in sufficient quantities. This can e.g. be done by using expression systems to express the gene encoding the protein of the 37 kD protein family.

45 [0019] An essential requirement for the expression of the nucleic acid sequence is an adequate promoter operably linked to the nucleic acid sequence. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression. Therefore, an even more preferred form of this embodiment relates to recombinant DNA molecules, i.e. DNA molecules according to the invention to which regulating sequences enabling expression of that nucleic acid sequence have been added. This can be obtained by means of e.g. standard molecular biology techniques. (Maniatis/Sambrook (Sambrook, J. Molecular cloning: a laboratory manual, 1989. ISBN 0-87969-309-6).

50 [0020] When the host cells are bacteria, useful expression control sequences which may be used include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inouge, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the  $\alpha$ -amylase (*B. subtilis*) promoter and operator, termination sequences and other expression enhancement and control sequences compatible with the selected host cell.

55 [0021] When the host cell is yeast, useful expression control sequences include, e.g.,  $\alpha$ -mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G.E. et al., Mol. Cell. Biol., 3, 2156-65, 1983). When the host cell is of mammalian origin illustrative useful expression control sequences include the SV-40 promoter (Berman, P.W. et al., Science, 222, 524-527, 1983) or the metallothionein promoter (Brinster, R.L., Nature, 296, 39-42, 1982) or a heat shock promoter (Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985). Alternatively, expression control sequences present in *Babesia* may also be applied. For maximising gene expression, see also Roberts and Lauer (Methods in Enzymology, 68, 473, 1979).

[0022] Bacterial, yeast, fungal, insect and mammalian cell expression systems are very frequently used systems. Such systems are well-known in the art and easily available, e.g. commercially through Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based expression systems are very attractive expression systems. Such systems are e.g. described in the French Patent Application

with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date 1 December 1993).

[0021] Another embodiment of the invention relates to Live Recombinant Carrier microorganisms (LRCs) comprising a gene encoding a protein of the 37 kD protein family according to the invention. Such micro-organisms are e.g. bacteria and viruses. These LRC micro-organisms are micro-organisms in which additional genetic information has been cloned. Animals infected with such LRCs will produce an immunogenic response not only against the immunogens of the vector, but also against the immunogenic parts of the polypeptide(s) for which the genetic code is additionally cloned into the LRC, e.g. the 37 kD protein.

As an example of bacterial LRCs, attenuated *Salmonella* strains known in the art can attractively be used.

[0022] Live recombinant carrier parasites have i.a. been described by Vermeulen, A. N. (Int. Journ. Parasitol. 28: 1121-1130 (1998))

Also, LRC viruses may be used as a way of transporting the nucleic acid sequence into a target cell. Live recombinant carrier viruses are also called vector viruses. The site of integration of the gene encoding a 37 kD protein may be a site in a viral gene that is not essential to the virus, or a site in an intergenic region. Viruses often used as vectors are Vaccinia viruses (Panicali et al; Proc. Natl. Acad. Sci. USA, 79: 4927 (1982), Herpesviruses (E.P.A. 0473210A2), and Retroviruses (Valerio, D. et al; in Baum, S.J., Dicke, K.A., Lotzova, E. and Pluznik, D.H. (Eds.), Experimental Haematology today - 1988. Springer Verlag, New York: pp. 92-99 (1989)).

[0023] The technique of *in vivo* homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid sequence into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid sequence according to the invention in the host animal.

[0024] Furthermore the invention relates to a host cell containing a nucleic acid sequence encoding the protein according to the invention, or a recombinant nucleic acid molecule encoding the protein under the control of regulating sequences enabling expression of the protein encoded by said nucleic acid sequence.

The invention also relates to a host cell containing a live recombinant carrier containing a nucleic acid molecule encoding a protein of the 37 kD family, or a recombinant nucleic acid molecule encoding a protein of the 37 kD family under the control of regulating sequences enabling expression of the protein encoded by said nucleic acid sequence. A host cell may be a cell of bacterial origin, e.g. *Escherichia coli*, *Bacillus subtilis* and *Lactobacillus* species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; Cell 32: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.

[0025] Another objective of the invention is to provide an efficient vaccine against *Babesia divergens* infection, or at least against the clinical manifestations of the infection.

It was now surprisingly found, that an immunological response that provides immunity against infection with the *Babesia* parasite, or at least an immunological response that sufficiently reduces the level of clinical manifestations upon infection (as shown e.g. by a decrease of the haematocrit value), can be obtained by vaccination with vaccines comprising a protein of the 37 kD protein family or an immunogenic fragment thereof.

[0026] When a polypeptide is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole polypeptide. It is also possible to use a fragment of that polypeptide that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that polypeptide, a so-called immunogenic fragment. An "immunogenic fragment" is understood to be a fragment of the full-length protein of the 37 kD family, that still has retained its capability to induce an immune response in the host, i.e. comprises a B- or T-cell epitope. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, US Patent NR. 4.833.092, Proc. Natl Acad. Sci. 81: 3998-4002 (1984), J. Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used worldwide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes. Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific polypeptide fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)), and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4.554.101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US 07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vac-

cine 10: 3-7 (1992), Berzowsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).

[0027] Therefore, another embodiment of the invention relates to vaccines inducing protection against infection with *B. divergens* or the clinical manifestations of the infection, comprising at least one protein of the 37 kD protein family or an immunogenic fragment thereof. It is clear that the protein of choice selected from the 37 kD protein family, or the gene encoding that protein can be a 35 kD protein or a 37 kD protein, or a mixture of the two. The protein or the gene encoding the protein can e.g. be chosen from *Babesia divergens* strain Rouen 1987 or Weybridge 8843 or any variants from other isolates.

[0028] More surprisingly it was also found, that proteins of the 37 kD protein family are capable of inducing antibodies that do not only protect against infection with a homologous *Babesia divergens* strain, but also with heterologous strains. This means i.a. that a vaccine based upon a 35 kD protein of e.g. *B. divergens* strain Weybridge induces protection against a 37 kD protein of e.g. *B. divergens* strain Rouen and *vice versa*.

Also, it was unexpectedly found that antibodies against a protein of the 37 kD protein family are capable of conferring *in vivo* immunity against both homologous and heterologous challenge.

This is the more surprising for the following reason: antibodies against the 17 kD protein mentioned above are abundantly found after experimental infection and after immunisation with fraction 4. Moreover,  $\alpha$ -Bd17, a monoclonal antibody against the 17 kD protein was described as the relevant vaccine component in passive vaccination against *Babesia* (Précigout et al., Experimental Parasitology 77: 425-434 (1993), see above) on the basis of the fact that it dramatically inhibits *in vitro* growth of the parasite. On the basis thereof, the 17 kD protein was expected to be the relevant vaccine component. This antibody however, when used as a reference in *in vivo* experiments, did unexpectedly not confer any protection at all, nor in a homologous nor in a heterologous challenge experiment (as will be seen in Example 4).

[0029] It was even more surprisingly found, that a vaccine comprising a mixture of two or more different proteins of the 37 kD family exhibit a synergistic effect compared to vaccines comprising the same amount of protein but from only one member of the 37 kD protein family. This has the advantage that vaccines comprising a mixture of two or more different proteins of the 37 kD protein family may comprise a lower overall amount of antigenic material compared to vaccines comprising a protein of only one member of the 37 kD protein family.

Thus in a preferred form, this embodiment of the invention relates to vaccines comprising two or more different proteins of the 37 kD protein family.

[0030] The following may serve as an example: a vaccine comprising a 35 kD protein and a 37 kD protein exhibits a synergistic effect compared to vaccines comprising the same amount of protein but from only 37 or 35 kD protein. A vaccine comprising both 50-75% of a 37 kD protein and 25-50 % of a 35 kD protein gives a level of protection against disease that is between 33% and 60% better than that found when the same amount of pure 37 kD protein or 35 kD protein was used as a vaccine. This holds true for challenge with strains comprising a 37 kD protein as well as for strains comprising a 35 kD protein. This has the advantage that relatively low amounts of immunogenic material can be used, yet giving rise to a sufficiently high immune response.

Such vaccines can be made e.g. by admixing the desired amounts of the purified proteins, but also by admixing the desired amounts of cells comprising the different proteins. Therefore, in a more preferred form, this embodiment of the invention relates to vaccines comprising both 50-75% of a 37 kD protein of the 37 kD protein family and 25-50 % of a 35 kD protein of the 37 kD protein family.

[0031] Such vaccines can alternatively be made by admixing live recombinant carriers encoding the 37 kD protein and encoding the 35 kD protein according to the invention.

Alternatively, in the case of DNA-vaccines, mixtures of recombinant DNA molecules each capable of expressing one of the proteins can be made.

[0032] It is clear, that a vaccine for the protection of cattle against *Babesia divergens* infection or the clinical manifestations thereof can also be based upon the administration of antibodies against a protein of the 37 kD protein family.

As a source of antibodies a polyclonal antiserum raised in e.g. rabbits against a member of the 37 kD protein family can be used. As described above, antisera against one protein of the 37 kD protein family show cross-protection against other proteins of the 37 kD protein family. Therefore, any protein of the 37 kD protein family can be used for the induction of such a polyclonal antiserum. Also, neutralising monoclonal antibodies against a protein of the 37 kD protein family, such as e.g. the monoclonal antibody F4.2F8 can be used.

Thus, the invention also relates to vaccines protecting against infection of cattle with *B. divergens* or the clinical manifestations of the infection, that comprise antibodies against a protein of the 37 kD protein family.

[0033] Also, a vaccine according to the invention may comprise a recombinant DNA molecule comprising a nucleic acid sequence according to the invention and regulating sequences enabling expression of that nucleic acid sequence as described above. Such a vaccine is capable of making the encoded protein of the 37 kD family in the host animal.

[0034] As an alternative to the administration of vaccines comprising proteins of the 37 kD protein family, vaccines can be administered that comprise an LRC carrying a gene encoding a protein of the 37 kD protein family or an immunogenic fragment thereof. The advantage of such an approach is, that such an LRC invades certain target cells of the host organism. Once inside the target cells all LRC-genes are expressed, including the gene encoding the protein of

the 37 kD protein family as carried by the LRC. As a result, the protein of the 37 kD protein family is expressed and presented to the immune system in a way that closely mimics the natural way of expression and immune presentation. Therefore, vaccination with a LRC carrying a gene of the 37 kD protein family or an immunogenic fragment thereof can advantageously be used.

5 Thus in another form of the embodiment relating to vaccines, the vaccine inducing protection against infection with *B. divergens* or at least against the clinical manifestations of the infection comprises a live recombinant carrier according to the invention.

[0035] When a vaccine is made on the basis of a protein of the 37 kD protein family or an immunogenic fragment thereof obtained from an expression system, in principle the protein can be purified from the proteins of the host cells 10 of the expression system. This is however not always necessary. It is very well possible to incorporate in a vaccine the cells that have been used for the expression of the protein of choice from the 37 kD protein family.

Thus, in still another form of the embodiment relating to vaccines, the vaccine inducing protection against infection with *B. divergens* or at least against the clinical manifestations of the infection, comprises a host cell according to the invention.

15 [0036] Additionally, the vaccine according to the invention may comprise one or more immunogenic proteins of other pathogens. This is advantageous, since vaccination with such a vaccine makes it possible to immunise an animal against two or more diseases in one vaccination step.

There are several ways of obtaining such a vaccine. One is admixing a protein according to the invention with one or 20 more immunogenic proteins of other pathogens. Another possibility is the cloning of a heterologous DNA sequence encoding an immunogenic protein of another pathogen into a live recombinant carrier according to the invention.

[0037] Preferably the immunogenic protein is chosen from the group of cattle pathogens, consisting of Bovine Herpesvirus, bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, *Pasteurella haemolytica*, Bovine Respiratory Syncytial Virus, *Theileria parva*, *Theileria annulata*, *Babesia bovis*, *Babesia bigemina*, *Babesia major*, *Trypanosoma species*, *Anaplasma marginale*, *Anaplasma centrale* or *Neospora caninum*.

25 [0038] Furthermore, the heterologous DNA sequence may encode a cytokine such as interleukins, TNF and interferons. Several cytokines, e.g. interferons are known to play an important role as immune modulators. Thus it may be advantageous to include genetic information for this kind of molecule into said section.

[0039] It is obvious that a heterologous DNA sequence can be introduced at a certain site in said section, e.g. in a 30 restriction site without deleting any nucleotides from the section. On the other hand, it is possible to exchange one or more nucleotides with heterologous DNA sequences of equal or different length.

[0040] Vaccines according to the present invention can be made e.g. by merely admixing of a protein of the 37 kD protein family or an immunogenic fragment thereof, either as such or coupled to a suitable carrier molecule, and a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier is understood to be a compound that does not 35 adverse effect the health of the animal to be vaccinated, at least not to the extend that the adverse effect is worse than the effects seen when the animal is not vaccinated. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.

Also, the vaccine can be made by admixing a nucleic acid sequence encoding a protein of the 37 kD family, a recombinant DNA molecule encoding a protein of the 37 kD family, a live recombinant carrier or a host cell according to the 40 invention and a pharmaceutically acceptable carrier.

[0041] Thus another embodiment of the invention relates to methods for the preparation of a vaccine comprising the admixing of a protein of the 37 kD protein family or an immunogenic fragment thereof, antibodies against a protein of the 37 kD family, a nucleic acid sequence according to the invention, a recombinant DNA molecule according to the invention, a live recombinant carrier according to the invention or a host cell according to the invention and a pharmaceutically acceptable carrier.

[0042] The vaccine according to the present invention may in a preferred presentation also contain an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host. A number of different adjuvants are known in the art. Examples of adjuvants are Freunds Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers and polyamines such as dextran sulphate, carbopol and pyran. Also very suitable are surface active substances such as Quil A<sup>(R)</sup>.

[0043] Saponins are a preferred adjuvant. Saponins are preferably added to the vaccine at a level between 20 and 150 µg/ml. Within the group of saponins, the saponin Quil A is a more preferred adjuvant.

Furthermore, peptides such as muramyl dipeptides, dimethylglycine, tuftsin, are often used. Next to these adjuvants, Immune-stimulating Complexes (ISCOMS), mineral oil e.g. Bayol<sup>(R)</sup> or Markol<sup>(R)</sup>, vegetable oils or emulsions thereof 55 and Diluvac<sup>(R)</sup> Forte can advantageously be used. The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the polypeptide adheres, without being covalently bound to it. Often used vehicle compounds are e.g. aluminium hydroxide, -phosphate, sulphate or -oxide, silica, Kaolin, and Bentonite. A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP

242.380).

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone polypeptides from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovarnik et al; J. Bacteriology 59: 509 (1950)), skimmed milk, gelatin, bovine serum albumin, carbohydrates e.g. sorbitol, manitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

5 Freeze-drying is an efficient method for conservation. Freeze-dried material can be stored and kept viable for many years. Storage temperatures for freeze-dried material may well be above zero degrees, without being detrimental to the material.

10 Freeze-drying can be done according to all well-known standard freeze-drying procedures.

Therefore, in a preferred embodiment, the vaccine is in a freeze-dried form.

In addition, the vaccine may be suspended in a physiologically acceptable diluent. Such a diluent can e.g. be as simple as sterile water, or a physiological salt solution.

It goes without saying, that other ways of adjuvanting, adding vehicle compounds or diluents, emulsifying or stabilising a 15 polypeptide are also embodied in the present invention.

[0044] The vaccine according to the invention can be administered in a conventional active immunisation scheme: single or repeated administration in a manner compatible with the dosage formulation, and in such amount as will be prophylactically effective, i.e. the amount of immunising antigen or recombinant micro-organism capable of expressing said antigen that will induce immunity in cattle against challenge by virulent *Babesia divergens* parasites. Immunity is

20 defined as the induction of a significant level of protection in a population of cattle after vaccination compared to an unvaccinated group.

[0045] For live viral vector vaccines the dose rate per animal may range from  $10^3$  to  $10^8$  pfu (but even <1000 pfu might be sufficient e.g. for Bovine Herpesvirus carrier virus). A typical subunit vaccine according to the invention comprises 0.1 to 100 $\mu$ g of the polypeptide (or variant or fragment thereof) according to the invention. Preferably at least 5 $\mu$ g 25 will be present. Such vaccines can be administered e.g. intradermally, subcutaneously, intramuscularly, intraperitoneally, intravenously, orally or intranasally.

[0046] An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)). In the field of anti-parasite vaccines, protection against e.g. Plasmodium yoelii has been obtained with DNA-vaccination with the Plasmodium yoelii circumsporozoite gene (Vaccine 12: 1529-1533 (1994)). Protection against Leishmania major has been obtained with DNA-vaccination with the Leishmania major surface glycoprotein gp63 gene (Vaccine 12: 1534-1536 (1994)). This way of vaccination is also very attractive for the vaccination of cattle against Babesiosis. Therefore, the invention also relates to vaccines comprising DNA encoding one or more proteins of the 37 kD protein family or an immunogenic 35 fragment thereof.

[0047] Since infection with *Babesia divergens* may progress relatively slowly, it may take some time before the diagnosis of *Babesia divergens* infection is made. In many cases in diseased animals *Babesia divergens* infection is only found to be the cause of the disease after the occurrence of haemoglobinuria (visible since it turns the urine red), which means that the disease has already significantly progressed.

40 Moreover, babesiosis infection is found in different forms. One form is characterised by the fact that *Babesia* antigens are found in the plasma, but no antibodies have yet been formed. This situation is found in acutely infected animals.

[0048] A second form is the form in which the *Babesia* parasites have been cured and the plasma does contain antibodies against *Babesia* antigens but no *Babesia* antigens. This is the situation found in animals that have developed a sterile immunity against *Babesia*. A third form is the form in which both antigens and antibodies are found in the 45 plasma. Animals having this form of infection are immune against *Babesia* but they are at the same time carrier of the parasite. These animals are a potential source of infection for other animals. Thus in order to determine the *Babesia* infection status of an animal it is important to determine both the *Babesia* antigen-levels and the anti-*Babesia* antibody-level in the serum. Therefore diagnostic tools, preferably capable of differentiating between the various forms, are highly wanted.

50 Another embodiment of this invention provides such diagnostic tools.

[0049] A diagnostic test for the detection of *Babesia divergens* antibodies in sera can be e.g. a simple ELISA-test in which purified protein of the 37 kD protein family or an antigenic fragment thereof is coated to the wall of the wells of an ELISA-plate. Incubation with serum from mammals to be tested, followed by e.g. incubation with a labelled antibody against the relevant mammalian antibody can then reveal the presence or absence of antibodies against the 37 kD protein.

55 Another example of a diagnostic test system is e.g. the incubation of a Western blot comprising 37 kD protein with serum of mammals to be tested, followed by analysis of the blot.

[0050] Thus, one form of this embodiment relates to a method for the detection in serum of antibodies against

*Babesia divergens* in which the method comprises the incubation of serum with protein of the 37 kD protein family or an antigenic fragment thereof.

[0051] A diagnostic test for the *Babesia* antigens and therefore suitable for the detection of *Babesia divergens* parasites can e.g. also be a standard ELISA test, in which the walls of the wells of an ELISA plate are coated with antibodies directed against a protein of the 37 kD protein family.

[0052] The invention also relates to methods for the detection of *Babesia divergens* parasites, that comprise the incubation of serum with antibodies against a protein of the 37 kD protein family.

[0053] A quantitative, or competition ELISA not only indicating the presence or absence of *Babesia* antigens but also indicating the amount of *Babesia* antigens, is also part of the invention. Such an ELISA is well-known in the art.

10 Thus this embodiment of the invention also relates to competitive ELISAs.

[0054] Antibodies or derivatives thereof (e.g. fragments such as Fab, F(ab')<sub>2</sub> or Fv fragments), which are directed against proteins of the 37 kD protein family according to the invention and have potential uses in passive immunotherapy, diagnostic immunoassays and in the generation of anti-idiotypic antibodies can be made according to standard techniques as indicated below.

15 The proteins or immunogenic fragments thereof according to the invention as characterised above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are known in the art (e.g. Mayer and Walter, eds. *Immunochemical Methods in Cell and Molecular Biology*, Academic Press, London, 1987).

20 Monoclonal antibodies, reactive against the protein according to the invention (or variants or fragments thereof) according to the present invention, can be prepared by immunising inbred mice by techniques known in the art (Kohler and Milstein, *Nature*, 256, 495-497, 1975).

Antibodies against any of the polypeptides of the present invention and made e.g. in one of the manners described above, can be used i.a. for vaccination purposes, especially in immunocompromised animals.

25 [0055] All kinds of antibodies against a protein of the 37 kDa protein family can be used in the diagnostic tests described above. Polyclonal antibodies obtained by injection of the Bd37 protein to an animal have a high affinity with all proteins of the 37 kDa protein family. Nevertheless, the antibodies of preference are specific antibodies made by the hybridoma cell line deposited with the ECACC under accession number 99031816. They have a high affinity with all proteins of the 37 kDa protein family tested so far.

30 [0056] The diagnostic tests for the detection of antibodies against *Babesia divergens* are preferably in the form of a kit, comprising 37 kD protein in a purified form. The antigens could e.g. be purified through standard protein separation techniques over a suitable column. Another possibility is separation on a PAAGE gel followed by Western-blotting. On the Western-blot, the 37 kD protein will form a specific band, separated from other *Babesia divergens* protein bands, and thus is also considered to be purified. Also, a pure form of the protein can be obtained by expressing one of the nucleic acid sequences according to the invention.

35 In principle, the easiest way of making such a diagnostic test system is to use purified whole 37 kD protein as explained above. It is however very well possible to use only part of the 37 kD protein. This with the proviso that the fragment used still comprises an antigenic determinant of the protein. All antigenic determinants of the 37 kD protein will induce antibodies by definition. Therefore, the use of a 37 kD protein fragment comprising even one single antigenic determinant of the 37 kD protein will be capable of binding to anti-37 kD protein antibodies.

40 Therefore, in another embodiment the present invention relates to a diagnostic kit for the detection of antibodies against *Babesia divergens*, in which the kit comprises a purified protein of the 37 kD protein family or fragments thereof still comprising an antigenic determinant.

45 As mentioned above, the protein can be purified directly from cells infected with the parasite. It is however also possible to use standard expression systems such as bacterial, parasite, yeast, baculovirus or mammalian expression systems, of which a large variety has been described in the art, for the expression of the 37 kD protein. The protein thus expressed can easily be purified.

[0057] In still another embodiment the present invention relates to a diagnostic kit for the detection of *Babesia divergens* parasites, in which the kit comprises antibodies reactive with an antigenic determinant on a protein of the 37 kD family.

50 [0058] Finally, still another embodiment of the invention relates to the use of a protein of the 37 kD protein family or a mixture of such proteins for the manufacture of a vaccine inducing protection against infection of cattle with *B. divergens* or the clinical manifestations of the infection. Such manufacture is described above where methods for the preparation of vaccines are described.

EXAMPLES :**Example 1.****5 Growth of *Babesia divergens* and Genomic DNA extraction**

[0059] An *in vitro* culture of *Babesia divergens* was grown according to Grande *et al.* (Parasitology, 115, 81-84 (1997)).

When parasitemia from *in vitro* culture reached 30 %, *B. divergens* parasitized erythrocytes were pelleted by centrifugation 5 min. at 2500 g.

Supernatant was centrifuged 20 min. at 15000 g : the pellet, containing merozoites, was washed twice in RPMI.

Infected red blood cells were lysed in 5 volumes of lysis buffer (5 mM EDTA ; 100 mM NaCl; 20 mM Tris pH 7.5; 0.5 % Triton X-100; 0.5 % SDS) supplemented with proteinase K at a final concentration of 1 mg/ml, 1 h at 37°C.

DNA extraction was performed in 3 steps with phenol, phenol-chloroform, and finally chloroform : isoamyl alcohol (24 :1) : addition of 1 volume of phenol or phenol-chloroform or chloroform : isoamyl alcohol (24 :1), vortex 1 min., centrifugation 5 min. at 10000 g, and transfer of the top aqueous phase in a fresh tube.

DNA was then precipitated by 2 volumes of cold ethanol 100 % and 1/10 volume of 3M sodium acetate pH 5.6, 1h at -80°C. After centrifugation 15 min. at 10000 g at 4°C, DNA pellet was washed with ethanol 70 %, dried and resuspended in sterile water.

20

**Plasmid miniprep**

[0060] A single plasmid colony was picked up into a tube containing 1.5ml of LB medium (10 g of bactotryptone, 5 g of yeast extract and 5 g of NaCl in 1 litre of distilled water, mixed and autoclaved), containing the appropriate antibiotic and incubated overnight at 37°C. Cells, pelleted by centrifugation 30 seconds at 10000 g, were firstly dissolved in 200 µl of a solution containing 100 mM Tris-HCl pH 7.5; 10 mM EDTA, secondly in 200 µl of a solution containing 200 mM NaOH, 1 % SDS and thirdly, after 5 min. at room temperature, in 200 µl of a solution containing 3 M potassium acetate and 5 M acetic acid. After incubation during 5 min. at 4°C and centrifugation 5 min. at 10000 g, plasmid DNA contained in the supernatant was precipitated by 0.7 volumes of isopropanol : it was then dissolved in 200 µl of TE buffer (10 mM Tris-HCl pH 7.5 ; 1 mM EDTA). For sequencing, a phenol-chloroform extraction and an ethanol precipitation were performed, as previously described.

**cDNA library construction**

35 [0061] A cDNA library was obtained from mRNA derived from *B. divergens* Rouen 1987 cultures as follows: 10<sup>9</sup> infected erythrocytes were pelleted by centrifugation of culture and treated by a lytic agent containing guanidine thiocyanate, using RNA-agents® Total RNA Isolation System kit (Promega). Total RNA were then purified by phenol : chloroform extraction and precipitated with isopropanol. With total RNA as the starting material, the poly(A) mRNA fraction was isolated by hybridisation to a biotinylated oligo(dT) primer, using PolyA Tract mRNA Isolation Systems kit (Promega). The hybrids were captured and washed at high stringency using streptavidin coupled to paramagnetic particles and a magnetic separation stand. mRNA were eluted by water and cDNA were synthesised, using ZAP Express™ cDNA Synthesis kit (Stratagene).

cDNA synthesis was performed by reverse transcription, using a primer which contains a poly(dT) sequence and a *Xba*I restriction site. *Eco*R I adapters were added to the 5' end of 0.4-4 kbp cDNA fragments (size-fractionated on Sephadryl S-500 spin Columns), after *Xba*I digestion. cDNA was ligated into the λ-ZAPII Express Vector in a sense orientation (*Eco*R I-*Xba*I) with respect to the lacZ promoter, using a ratio of 150 ng of cDNA to 1 µg of vector. Recombinant lambda phages were then packaged in Gigapack II packaging extracts from Stratagene, and plated on NZY agar plates, using XL1-Blue MRF' cells, to be amplified and titered as recommended by the manufacturer (Stratagene).

**50 cDNA library screening**

[0062] The polyclonal antibody directed against the 37 kDa protein family (α-Bd37) was used for the screening of the cDNA library of *B. divergens* Rouen 1987.

For screening, 4000 recombinants of the cDNA library were plated using XL1-Blue MRF' cells. After 8 hours growth at 37°C, recombinant β-galactosidase from each clone was blotted during 3 hours onto membranes of nitrocellulose, saturated with 10 mM IPTG. Discs were then saturated overnight in TBS (150 mM NaCl, 20 mM Tris-HCl pH 7.2) + 5 % non fat milk at 4°C, washed in TBS and incubated 1 h with the α-Bd37 at a dilution of 1:250. Positive plates were visualised using goat anti-rabbit IgG conjugated to peroxidase, at a dilution of 1:500.

## EP 1 050 541 A1

[0063] Positive plates were transferred in 500 µl of SM buffer, incubated 1 h at 37°C and stored at 4°C. Following purification of these positive plates, cDNA encoding the 37 kDa protein was excised out of the λ-ZAPII phage in the form of the kanamycin resistant pBK-CMV phagemid vector, using a helper phage, as recommended by Stratagene.

### 5 cDNA sequencing

[0064] 4 µg of plasmids carrying cDNA encoding the 37 kDa protein of *B. divergens* Rouen were sequenced by using the T<sub>7</sub> Sequencing™ kit (Pharmacia Biotech). After denaturation with NaOH, neutralisation and ethanol precipitation, cDNA was pelleted by centrifugation and resuspended in 10 µl of water. Annealing reactions were made using 10 pmol of primer and then, DNA were sequenced using the dideoxy method of Sanger *et al.*((1977), *Proc. Natl. Acad. Sci. USA* 74 (12) : 5463-7), using the reagents and procedures of Pharmacia Biotech. Primers useful for reading the entire sequence were synthesised by Eurogentec.

### 15 Analysis of the cDNA sequence encoding the 37 kDa protein

[0065] The sequence of the cDNA encoding the 37 kDa protein (1208 bp between restrictions sites EcoRI and Xhol) showed the presence of a poly(A)<sub>18</sub> tail and a coding region of 1023 desoxyribonucleotides, giving a single open reading frame of 341 amino acids, without repetitive motif.

Analysis of the hydrophilicity profile revealed two hydrophobic sequences, at each extremity of the protein : from amino acids 1 to 18 at the N-terminal end and from amino acids 321 to 341 at the C-terminal end of the protein. The hydrophobic segment at the N-terminal end could correspond to the signal sequence of the 37 kDa protein and the presence of such a cleavable N-terminal signal sequence suggested that the 37 kDa protein is a secreted protein. However, the presence of another hydrophobic segment at the C-terminal end of the molecule indicated that the 37 kDa protein could interact or be anchored in the membrane of parasitic vesicles during the secretory pathway to be on the surface of the parasite at the end of this process. These observations are consistent with the pattern of immunofluorescence obtained on *B. divergens* infected erythrocyte since the labelling was observed both inside parasitic vesicles and on the surface of the parasite. The finding of the 37 kDa protein in the supernatant of *in vitro* culture could result in a cleavage of the molecule either from the surface of the parasite or from secreting vesicles.

### 30 Cloning of the 37 kDa protein gDNA from different isolates of *B. divergens* in pGEM®-T Vector

[0066] Genomic DNA (gDNA) of the *B. divergens* Rouen 1987, Weybridge 8843 and Y5 isolates were amplified by Polymerase Chain Reaction (PCR) and cloned in pGEM®-T vector System II (Promega), in order to be sequenced as described above.

35 gDNA from *B. divergens* Rouen 1987 and Weybridge 8843 were amplified using primer Bd37-5 (sense oligonucleotide), 5'-GAATTACGACCATACTAATA-3', and Bd37-Low (antisense oligonucleotide), 5'-ACAGGATCCAAAAGCTA-CATAGCTGTCCACT-3', whereas gDNA from *B. divergens* Y5 were amplified using primer Bd37-Upp (sense oligonucleotide), 5'-CAAGGATCCTCTAACGTACGATGAAAACAGTAA-3', and Bd37-Low. To perform the PCR, 100 ng of each gDNA were incubated with 0.5 µl of each primer at 10 µM, 4 µl of dNTP (1.25 mM each), 2.5 µl of 10X enzyme buffer and 1 unit of *Taq* DNA polymerase (Ozyme), in a final volume of 25 µl. The following conditions were used : 3 min. at 94°C, 30 cycles of 1 min. at 94°C, 1 min. at 50°C and 2 min. at 72°C, and then 5 min. at 72°C.

40 PCR products were purified by electroelution : they were subjected to a 1 % agarose gel electrophoresis. The expected band was visualised under UV, excised and subjected to electroelution in 400 µl of TAE buffer, at 100 mA during 1 h. The electroeluted materials was phenol extracted and ethanol precipitated as described above.

45 The ligation reaction was performed by adding 50 ng of each gDNA to 50 ng of pGEM vector, and 3 units of T4 DNA ligase in 1 µl of the 10X appropriate buffer, during 5 h at 16°C. 2 µl of each ligation mix were used for the transformation reaction, in JM109 High Efficiency Competent Cells, as recommended by Promega.

50 Recombinant vectors were visualised, using blue-white screening : some white colonies were picked up and transferred in 50 µl of sterile water. After vortex, tubes were boiled for 5 min. and centrifuged 1 min. at 10000 g : 10 µl of the supernatant were used for a PCR reaction as described above, with T3 and T7 primers, in order to verify the presence of the insert. For sequencing of the insert, a culture of 1,5 ml in LB of the recombinant vector was used for a plasmid miniprep, as previously described.

### 55 Characterisation of genes as encoding a protein of the 37 kD protein family by hybridisation.

[0067] For hybridisation experiments 4 µg of genomic DNA is digested by 20 units of *Pst* I restriction enzyme, 3 h at 37°C and digested products are submitted to a 0.8 % agarose electrophoresis. After denaturation and neutralisation, DNA is transferred to Hybond-N membrane (Amersham) and fixed by UV. The DNA to be tested is labeled using Nick

Translation kit (Boehringer Mannheim), with the Redivue™ [ $\alpha$ -<sup>32</sup>P]dCTP (3000 Ci/mmol) at a final concentration of 20  $\mu$ Ci (Amersham) and then purified using Probe Purification after labelling kit (Jetnick) as recommended by manufacturer. Membranes are firstly incubated in a prehybridization solution (5xSSC, 0.5 % SDS and 1 g/l of Ficoll type 400, Polyvinylpyrrolidone and Bovine Serum Albumine), 1 h at 65°C and then hybridized overnight at 65°C in 10 ml of the same solution, supplemented with 1 mg of herring sperm DNA and the denatured labelled probe. Membranes are washed three times for 15 min. at 65°C in 6xSSC and exposed to Biomax MR-1 film (Polylabo) at -80°C, during 48 hours.

DNA that hybridises to the DNA on the Hybond-N membrane comprises a gene encoding a protein of the 37 kD protein family.

10

### Example 2

#### Cloning of the Bd37 cDNA in the pGEX-A vector

[0068] In order to express a recombinant Bd37 protein, the cDNA was sub-cloned in the *E. coli* vector pGEX-A. In a first step, the entire coding region of the cDNA was amplified by PCR using primers Bd37-Upp (sense oligonucleotide) and Bd37-Low (antisense oligonucleotide), which contain *Bam*H restriction sites. The PCR products were then sub-cloned in the pGEM®-T vector, as described above. In a second step, 500ng of pGEX-A vector and 500ng of the pGEM®-T vector containing Bd37 cDNA were digested with 30 units of *Bam*H restriction enzyme, 3 h at 37°C, in the appropriate buffer (Life technologies), in order to be ligated.

After phenol/chloroform extraction and ethanol precipitation, the pGEX-A vector was dephosphorylated, using 0.0015 units of Calf Intestinal Alkaline Phosphatase (Promega), 1 h at 37°C in the appropriate buffer and reprecipitated. The excised cDNA fragment was purified by electroelution, as described above.

The ligation of 100 ng of *Bam*H-cut phosphatase treated pGEX-A vector with 100 ng of Bd37 cDNA fragment was performed using 15 units of T4 DNA ligase, in the appropriate buffer, during 1 h at 25°C. 1  $\mu$ l of the ligation mix were used to transform 75  $\mu$ l of Epicurian Coli® SURE®2 supercompetent cells, as recommended by the manufacturer (Stratagene).

Recombinants were determined by hybridisation : Hybond-N (Amersham) filters were applied 30 seconds on plates, denatured 1 min. with 1.5M NaCl, 0.5N NaOH and neutralised with 1.5 M NaCl, 0.5 M Tris-HCl pH 7.5. The filters were rinsed in 2xSSC, air dried and exposed, DNA side up, to UV ( $\lambda > 254$ nm) during 3 min.

A PCR was performed on *B. divergens* Rouen 1987 cDNA, using internal primers Bd37-E1 (sense oligonucleotide), 5'-CAAGGTGGTGCATTCAAAG-3' and Bd37-E4 (antisense oligonucleotide), 5'-ATACAATGATACCGAATTCAATGG-3'. 0.2  $\mu$ g of the electroeluted PCR fragment were used to synthesise a nucleotide probe using Nick Translation kit (Boehringer Mannheim). The probe was labelled with the Redivue™ [ $\alpha$ -<sup>32</sup>P]dCTP (3000 Ci/mmol) at a final concentration of 20  $\mu$ Ci (Amersham). The excess of triphosphate deoxyribonucleosides were discarded on a column of glass beads (Glasperlen 0.25-0.3  $\mu$ m from Braun) and Sephadex® G50 superfine (Pharmacia).

Membranes were prehybridised in 6xSSC + 2.5% non fat milk, 1 h at 65°C, and hybridized overnight at 65°C in 6xSSC + 2.5% non fat milk containing herring sperm DNA at 100  $\mu$ g/ml and the denatured labelled probe. Membranes were washed three times for 15 min. at 65°C in 6xSSC and exposed to Biomax MR-1 film (Polylabo) at -80°C, during two hours.

The correct orientation of the Bd37 fragment in the positive recombinant pGEX-A vector was controlled by performing PCR on the purified recombinant vector using the 5'pGEX primer (Pharmacia), combined with the internal Bd37-E4 primer.

[0069] The same procedure has been followed, using 100 ng of genomic DNA from *B. divergens* Weybridge 8843 as the starting material, in order to clone a gene encoding a 35 kDa protein in the pGEX-A vector and to express a recombinant Bd35 protein.

[0070] Lastly, as a control, 100 ng of native pGEX-A vector were used to transform 75  $\mu$ l of Epicurian Coli® SURE®2, supercompetent cells, in order to produce native glutathione S-transferase (GST).

50 Production of recombinant GST, GST-Bd37 and GST-6d35 proteins for a vaccination assay.

[0071] The different constructs, which express GST or a fusion protein of Bd37 or Bd35 protein with GST, were induced by IPTG. The bacterial cultures were grown overnight and diluted 1:10 with LB-medium supplemented with ampicillin at 50  $\mu$ g/ml. The cultures were incubated for 1 h at 37°C and then induced with 10<sup>-4</sup>M IPTG during 3 h. The bacteria were lysed by sonication in MTPBS (150mM NaCl, 16mM Na<sub>2</sub>HPO<sub>4</sub>, 4mM NaH<sub>2</sub>PO<sub>4</sub>, pH 7.3)-1% Triton X-100 and the recombinant proteins were purified by affinity on glutathione-agarose beads and eluted by competition with reduced glutathione (Smith D.B. and Johnson K.S. (1988), *Gene* 67(1): 31-40).

**Production of a recombinant 37 kDa protein in insect cells for a vaccination assay**

[0072] For the production of the recombinant DNA in baculovirus, the cDNA encoding the 37 kDa protein was cloned according to standard procedures into the Bac-to-Bac™ vector provided by Life Technologies, 8717 Grovemont Circle, P.O. box 6009, Gaithersburg, MD 20884-9980, U.S.A.

Six T75 flasks were used for the culture of infected and non-infected SF9 cells, containing each  $7.5 \times 10^6$  SF9 cells in a final volume of 15 ml of HYQ CCM3 medium (Hyclone Europe NV, Belgium) : three of these flasks were infected with 52.5 µl of Bd37-1 virus ( $6.9 \times 10^7$  pfu/ml), which correspond to an infection of SF9 cells at a multiplicity of infection of 0.5. Infected and non-infected cells (NIC) were collected 60 h post-infection in a final volume of 7.5 ml of CCM3 medium and treated by 0.3 % Triton X-100, 1 h at room temperature. An aliquot of 100 µl of infected and non-infected cells were dissociated in 10 µl of 10X Sample Buffer and boiled during 5 min. Two aliquots of 25 µl from each sample (one used for a Coomassie Blue staining and one used for an immunoblotting using the monoclonal antibody F4.2F8 at a dilution of 1:50) were submitted to a 12 % SDS-PAGE. These infected cells, expressing the 37 kDa protein, and non-infected cells have been used to immunise gerbils, in order to test the immunoprotective effect of the 37 kDa protein.

**Example 3****Vaccination assay with a recombinant 35 and 37 kD protein of the 37 kDa protein family.**

[0073] The vaccination assay has been conducted on 15 groups of 10 gerbils, in order to test the immunoprotective effect of the recombinant Bd37 protein, either expressed in the prokaryotic system (using the fusion proteins GST-Bd37 or GST-bd35) or in the eukaryotic Bac-to-bac system (using the recombinant Bac-Bd37). Three different doses of recombinant proteins, comprising of 5 µg, 25 µg and 125 µg, have been tested (See table 1). Negative controls groups have only received the equivalent of native GST or non infected insect cells. Each vaccine preparation have been adjuvanted with the Quil-A adjuvant. A positive control group have received 300 µl of supernatant from *B. divergens* Rouen 1987 *in vitro* culture. A challenge control group only received  $10^6$  parasitized erythrocytes.

**Animals**

[0074] Gerbils (7-8 weeks of age) were used. The animals received food and water ad libitum.

**Parasites**

[0075] The challenge strain used was *B. divergens* Rouen 1987 and each animal received  $10^6$  parasitized erythrocytes in a final volume of 100 µl.

**Vaccine preparation**

[0076] Recombinant proteins (GST, GST-Bd35 or GST-Bd37 protein, infected or non-infected insect cells lysate) were produced as described above. (cf. fig. 3)

Supernatant from *B. divergens* Rouen 1987 *in vitro* culture was harvested when parasitemia reached 30-40% in RPMI-Albumax, centrifuged at 10000 g for 15 min., passed through a filter-membrane (0.22 µm pore-size ; Gelman Sciences) and stored at -80°C until use.

[0077] Each preparation (GST, GST-Bd35 or GST-Bd37 protein, infected or non-infected insect cells lysate and supernatant from *in vitro* culture) was diluted in RPMI in order to obtain 12 doses each containing the expected quantity of recombinant protein (or equivalent) in a final volume of 3.4 ml. 100 µl of a stock solution Quil A at 2.8 mg/ml have been added to each vaccine preparation. A dose of 300 µl has been injected subcutaneously to each gerbil.

Table 1

Group	Vaccine	Quantity	Nb of injection	Challenge
1	GST-Bd37	5µg	2	R
2	GST-Bd37	25µg	2	R
3	GST-Bd37	125µg	2	R
4	GST-Bd35	25µg	2	R

Table 1 (continued)

Group	Vaccine	Quantity	Nb of injection	Challenge
5	GST	2,5µg	2	R
6	GST	12,5µg	2	R
7	GST	62,5µg	2	R
8	bac-Bd37	5µg	2	R
9	bac-Bd37	25µg	2	R
10	bac-Bd37	125µg	2	R
11	NIC	5µg	2	R
12	NIC	25µg	2	R
13	NIC	125µg	2	R
14	SN R	300µl	2	R
15	/	/	2	R

R : *B. divergens* Rouen 1987 strain  
NIC : non-infected insect cells  
SN R : supernatant from *B. divergens* Rouen 1987 *in vitro* culture

**Vaccination procedure**

[0078] Priming and booster infections have been done subcutaneously with a 3 weeks interval. Animals were challenged with *B. divergens* Rouen 1987 intraperitoneally, 3 weeks after the booster injection, with  $10^6$  parasitized erythrocytes (100 µl)/gerbil.

[0079] At days D-43, D-22 and D-1, a blood sample has been collected from the animals of each group. The serum samples of each group were tested by immunoprecipitation and immunofluorescence in order to analyse the humoral response of the gerbils against the recombinant 37 kDa protein.

**Results****35 Immunoprecipitation**

[0080] The sera from each gerbil, from D-43, D-22 and D-1, were used to immunoprecipitate  $^{35}$ S-radiolabelled *B. divergens* Rouen 1987 total antigens.

Firstly, from figure 4, it can be seen that non-infected insect cells and native GST are not immunogenic in the sense that the humoral response doesn't cross-react with *B. divergens* antigens (groups 5 to 7 and 11 to 13) : the pattern observed corresponds to the non-specific response.

For all the sera from gerbils vaccinated with the 37 kDa recombinant protein, a strong humoral response against the protein is specifically observed (groups 1 to 4 and 8 to 10), whereas controls vaccinated with NIC (non-infected cells) or native GST are negative.

45

50

55

## Protection

[0081]

Table 2A :

Groups	1	2	3	4	5	6	7
Challenge doses	$10^6$ para-sites						
Challenge strain	R	R	R	R	R	R	R
Number of gerbils	9	10	10	10	10	10	10
Vaccine	GST-37	GST-37	GST-37	GST-35	GST	GST	GST
Dose ( $\mu$ g)	5	25	125	25	2,5	12,5	62,5
Number of gerbils	9	10	10	10	0	0	0

Table 2B :

Groups	8	9	10	11	12	13	14	15
Challenge doses	$10^6$ para-sites							
Challenge strain	R	R	R	R	R	R	R	R
Number of gerbils	9	10	10	10	10	10	10	10
Vaccine	Bac-Bd37	Bac-Bd37	Bac-Bd37	NIC	NIC	NIC	SN R	/
Dose ( $\mu$ g)	5	25	125	5	25	125	300 $\mu$ l	/
Number of gerbils	8	10	8	1	1	0	10	0

Table 2 : Protection with recombinant 37 kDa protein expressed in a prokaryotic (A) or eucaryotic (B) system

## Conclusion

[0082] As can be seen from Table 2A, a total immunoprotection is conferred to gerbils vaccinated with GST-Bd37 and GST-Bd35, respectively against a homologous or heterologous challenge with *B. divergens* Rouen 1987 (which encodes a 37kDa protein). Gerbils did not present any fall of haematocrit and any positive parasitemia. These results were obtained with very low (5  $\mu$ g) doses as well as with high doses (125  $\mu$ g) of recombinant protein. Contrary to this, all control gerbils, vaccinated with native GST, died.

From Table 2B it can be seen that very good results were also obtained for gerbils vaccinated with recombinant Bac-Bd37, even taking into account that the Bd37 protein was not purified. Even if gerbils received a high dose of insect cells lysate, the level of protection reached 80 to 100 %, according to the dose tested, whereas control gerbils, vaccinated with non-infected insect cells, all died except one.

It can be concluded, that protein of the 37 kD protein family gives very high level protection regardless the expression

system used.

**Example 4.**

5 **Passive immunisation with monoclonal antibodies F4.2F8 and homologous or heterologous challenge**

[0083] Hybridoma producing the mAb F4.2F8 were grown and the monoclonal antibodies were purified according to standard procedures for the preparation of monoclonal antibodies. The monoclonal antibodies were injected intraperitoneally in gerbils and the concentrations of F4.2F8 were maintained by multiple injections, starting one day before the challenge and continuing several days after.

10 As an antibody concentration of 100 µg/ml is needed (1 % of total gerbil immunoglobulins), 0.5 mg of antibodies in culture medium was daily injected per gerbil. The experiment was continued during 7 days after challenge.

[0084] Two different challenge strains were used : *B. divergens* Rouen 1987 (comprising the 37 kDa protein) and Weybridge 8843 (comprising the 35 kDa protein). Gerbils were challenged by a high dose ( $10^6$  parasitized erythrocytes by gerbil) or a low dose ( $10^3$  parasitized erythrocytes by gerbil). The volume of the challenge dose ( $10^6$  PE or  $10^3$  PE) was 100 µl.

15 For each strain of challenge, a first control group (isotype control) has received an unrelated mouse monoclonal antibody IgG2a, which is an antibody against a non-37 kDa protein having however the same isotype as F4.2F8, in order to test the non-specific activity. A second control group (antibody control) has received the monoclonal antibody  $\alpha$ -

20 Bd17, directed against another *B. divergens* protein, the 17 kDa protein described above (Précigout *et al.* (1993), *Exp. Parasitol.* 77 (4): 425-34). A last control has not received any injection of antibodies (no antibody control), in order to control the virulence of the strains.

**Results**

25

[0085]

	A-Homologous		B-Heterologous	
	Rouen (37 kDa) $10^6$ parasites	Rouen (37 kDa) $10^3$ parasites	Weybr. (35 kDa) $10^6$ parasites	Weybr. (35 kDa) $10^3$ parasites
mAb F4.2F8	100	100	100	100
$\alpha$ -Bd17 control	n.d.	30	n.d.	10
isotype control	n.d.	20	n.d.	40
no antibody control	0	20	0	0

45

Table 3 : homologous (A) and heterologous (B) challenge results after passive immunisation

50

**Conclusion**

**homologous challenge results**

55

[0086] As is clear from Table 3A, vaccination with antibodies specifically raised against the 37 kDa protein gives full protection against infection with a homologous *Babesia divergens* strain. This corroborate the fact that the 37 kDa protein according to the invention is capable of triggering antibodies providing full protection against homologous chal-

lenge.

#### **heterologous challenge results**

5 [0087] As follows from Table 3B, the 37 kDa antibodies do not only provide full protection against homologous challenge (a strain expressing the 37 kDa protein), but also against heterologous challenge (a strain expressing the 35 kDa protein).  
 Therefore it can be concluded that proteins of the 37 kDa protein family according to the invention induce an antibody response that gives protection against challenge with both homologous *Babesia divergens* strains but also against heterologous strains.  
 10

#### **Example 5.**

##### **Synergistic effect of vaccines comprising both a 35 kD protein and a 37 kD protein of the 37 kD protein family**

###### **Vaccine preparation**

15 [0088] *B. divergens* Rouen en Weybridge parasites were propagated in human erythrocytes in RPMI 1640 medium supplemented with 5 g/l Albumax®. Culture supernatants were harvested at 30-40% parasitaemia, and passed through a 0.22 µm filter. The total volume was kept at 250 µl. One dose of vaccine contained 23.3 µg of Quil A.  
 20

###### **Immunisation procedure**

25 [0089] Vaccination of gerbils was done with volumina of 250 µl, comprising supernatant of Rouen/Weybridge in a ratio of 0/100, 25/75, 50/50, 75/25 and 100/0. Vaccination was done twice, with a three week interval.

###### **Challenge**

30 [0090] Gerbils were challenged intraperitoneally with  $10^3$  or  $10^6$  parasitized erythrocytes/250µl/gerbil at three weeks after booster injection.  
 Challenge strain 7107b was passed through gerbils to prepare the challenge inoculum. After developing babesiosis, animals were sacrificed and the level of parasitaemia was determined.

###### **Rank score analysis**

35 [0091] Survival, minimal PCV (Packed Cell Volume = haematocrite) and parasite load were submitted to rank score analysis. For each parameter, groups were ranked. The best group was ranked 1, the second best 2 and so on. After ranking the different parameters the total scores for each group were determined. The total net rank score was expressed as the difference between the control and vaccinated groups. This total score can be described as new parameter: protection based upon the different parameters mentioned above.  
 40

###### **Results.**

45 [0092] As can be clearly seen from figure 5, a vaccine based upon a mixture of both 35 kD and 37 kD proteins according to the invention gives a better protection against challenge with both strains comprising 35 kD and 37 kD protein, compared to vaccines based upon the same amount of protein from only a 35 kD or a 37 kD protein.

###### **Conclusion.**

50 [0093] Vaccination with a mixed vaccine comprising both 35 kD and 37 kD protein has a synergistic effect. Such a vaccine protects, when given in low (i.e. below the optimal protective) doses, even better against challenge with both homologous and heterologous strains than comparable low amounts of vaccines based upon pure 35 kD or 37 kD protein.  
 55

**Legend to the figures**

[0094]

5      Figure 1: Alignment of nucleic acid sequences encoding protein of the 37 kDa protein family in *B. divergens* strains Rouen 1987, Weybridge and Y5, respectively SEQ. ID. NO: 1, 2 and 3 by Clustal method.

10     Figure 2: Alignment of amino acid sequences of the 37 kDa protein family in *B. divergens* strains Rouen 1987, Weybridge and Y5, respectively SEQ. ID. NO : 4,5 and 6 by Clustal method.

15     Figure 3: Recombinant proteins of the 37 kD protein family were produced either in a prokaryotic system (A) or in a eukaryotic baculovirus (Bac-to-bac) system (B). The following proteins are visible on gel: purified GST-Bd37 (lane 1) and GST-Bd35 (lane 2) fusion proteins, infected cell lysate containing the Bac-Bd37 protein (lane 3) and non-infected insect cell lysate (lane 4).

20     Figure 4: Immunoprecipitation of antigens from *B. divergens* Rouen 1987 by sera from gerbils vaccinated with recombinant Bd37 proteins.

25     Figure 5: Total net rank score of minimal PCV, parasite load and survival of gerbils vaccinated with a mix of Weybridge and Rouen SPA (Soluble Parasite Antigen) challenged with a high or a low challenge dose.

30

35

40

45

50

55



**EP 1050 541 A1**

	30	35	40	
5	cc <del>t</del> ggg aat gat g <del>g</del> g <del>a</del> c <del>a</del> g <del>a</del> g <del>c</del> g <del>t</del> g <del>g</del> t a <del>c</del> g <del>g</del> t a <del>g</del> c <del>a</del> g <del>g</del> t g <del>g</del> a <del>a</del> c <del>a</del> 255 Pro Gly Asn Asp Ala Gln Gln Ala Gly Thr Gln Gln Gly Gly Ala Asn			
45	50	55	60	
10	t <del>c</del> a <del>a</del> g <del>g</del> t <del>c</del> c <del>t</del> t <del>a</del> g <del>a</del> g <del>a</del> c <del>a</del> g <del>a</del> g <del>c</del> g <del>t</del> g <del>g</del> c <del>g</del> g <del>a</del> a <del>c</del> 303 Ser Lys Ser Val Pro Glu Gln Gln Pro Gln Gln Ala Ala Gly Glu Thr			
	65	70	75	
15	a <del>c</del> t <del>g</del> a <del>c</del> g <del>t</del> c <del>t</del> g <del>t</del> g <del>t</del> a <del>a</del> a <del>c</del> t <del>t</del> g <del>a</del> t <del>g</del> c <del>t</del> c <del>t</del> c <del>t</del> g <del>t</del> g <del>g</del> g <del>a</del> a <del>c</del> 351 Thr Ala Thr Val Val Val Lys Thr Leu Asp Val Leu Arg Gly Glu Ieu			
20	80	85	90	
	a <del>g</del> g <del>g</del> c <del>a</del> g <del>c</del> g <del>t</del> g <del>a</del> g <del>c</del> g <del>t</del> t <del>t</del> c <del>t</del> t <del>a</del> g <del>a</del> a <del>t</del> a <del>t</del> a <del>a</del> t <del>c</del> g <del>a</del> t <del>g</del> g <del>g</del> 399 Arg Gly Gln Arg Glu Ala Phe Leu Ser Glu Ile Ile Lys Ser Asp Gly			
25	95	100	105	
	c <del>c</del> t <del>t</del> a <del>c</del> t <del>t</del> t <del>t</del> c <del>a</del> g <del>t</del> g <del>t</del> g <del>g</del> t <del>a</del> c <del>t</del> t <del>t</del> c <del>t</del> g <del>t</del> g <del>a</del> c <del>a</del> 447 Pro Phe Thr Ile Leu Gin Leu Val Gly Tyr Leu Arg Val Val Asp Thr			
30	110	115	120	
	g <del>a</del> t <del>t</del> c <del>t</del> c <del>t</del> c <del>t</del> g <del>a</del> a <del>t</del> g <del>t</del> t <del>a</del> c <del>a</del> g <del>a</del> a <del>t</del> g <del>t</del> g <del>a</del> g <del>c</del> g <del>c</del> a <del>a</del> 495 Asp Leu Leu Leu Lys Val Asp Ser Thr Lys Val Asp Glu Ala Gly Lys			
35	125	130	135	140
	a <del>a</del> g <del>t</del> a <del>a</del> g <del>c</del> t <del>a</del> c <del>t</del> g <del>a</del> a <del>a</del> a <del>t</del> g <del>g</del> a <del>t</del> a <del>a</del> t <del>g</del> g <del>g</del> t <del>t</del> g <del>t</del> 543 Lys Val Lys Ala Tyr Leu Glu Lys Ile Gly Ile Arg Gly Asp Ser Val			
40	145	150	155	
	g <del>a</del> g <del>c</del> g <del>c</del> c <del>t</del> g <del>a</del> a <del>a</del> t <del>t</del> a <del>t</del> g <del>t</del> a <del>t</del> a <del>a</del> t <del>g</del> t <del>a</del> g <del>a</del> a <del>c</del> a <del>a</del> 591 Glu Ala Ala Leu Asp Asn Leu Met Ile Lys Val Tyr Glu Ile Thr Lys			
45	160	165	170	
	g <del>g</del> t <del>a</del> g <del>t</del> g <del>a</del> a <del>g</del> t <del>c</del> g <del>c</del> a <del>a</del> g <del>g</del> t <del>a</del> c <del>a</del> g <del>a</del> t <del>g</del> g <del>a</del> c <del>t</del> g <del>a</del> 639 Gly Thr Val Glu Ser Ser Ala Gln Gly Thr Asp Ser Glu Glu Leu Lys			
50	175	180	185	
55				

EP 1050 541 A1

act ttc tta tta aag ttc agc gaa gat ctc aag gct gag caa gaa ctt 687  
Thr Leu Leu Leu Lys Phe Ser Glu Asp Leu Lys Ala Glu Gln Glu Leu  
5 190 195 200

cat agt gaa gcc aag ggc ggt gag gac ttt tct atg atg aag acg 735  
His Ser Glu Ala Lys Gly Gly Glu Ala Leu Leu Ser Ser Met Lys Thr  
10 205 210 215 220

cag cat gat gaa cta ctt aag aag ttt gct gcc ctt acc cct act ttc 783  
Gln His Asp Glu Leu Leu Lys Lys Phe Ala Ala Leu Thr Pro Thr Phe  
15 225 230 235

tta acc tca gag gat ata tat gyc tac ctt acc gtc ccg gaa tac ggt 831  
Leu Thr Ser Glu Asp Ile Ser Gly Tyr Leu Thr Val Pro Glu Tyr Gly  
20 240 245 250

gcc cct atq aat gct gcg aag tgg aaa aag gtc gaa gga atq atc cat 879  
Ala Pro Met Asn Ala Ala Lys Trp Lys Lys Val Glu Gly Met Ile His  
25 255 260 265

gga aag ctc gag tct tct gaa gta cca gct aat ctc aaa gct ctg gtt 927  
Gly Lys Leu Glu Ser Ser Glu Val Pro Ala Asn Leu Lys Ala Leu Val  
30 270 275 280

gca gaa tta att gaa ttc ggt gaa gag atg atg gat ttc cta tac ggc 975  
Ala Glu Leu Ile Glu Leu Arg Glu Gln Met Met Asp Leu Leu Tyr Gly  
35 285 290 295 300

cct att gct cat caa gat tgc gct gca gga tca ggt cag gga tct agt 1023  
Pro Ile Gly His His Asp Cys Ala Ala Gly Ser Gly Gln Gly Ser Ser  
40 305 310 315

cct aag aag cca tcc ttc gct gct gta cct tct tct ttg tct gcc att 1071  
Pro Lys Lys Pro Ser Phe Ala Ala Val Pro Ser Ser Leu Ser Ala Ile  
45 320 325 330

gtc ttc ggt atc att gta tca atg ttc taa gtggacagct atgttagctt 1121  
Val Phe Gly Ile Ile Val Ser Met Phe  
50

55

335

340

5 tggatcttgt

1131

10 <210> 2  
 <211> 341  
 <212> PRT  
 <213> Babesia divergens

15

<400> 2  
 Met Lys Thr Ser Lys Ile Leu Asn Thr Ala Ala Ile Cys Leu Leu Ala  
 1 5 10 15

20

Met Gly Phe Asn Gly Asn Asn Val Val Cys Thr Asn Leu Asn Gly Ser  
 20 25 30

25

Gln Glu Pro Ala Ala Ala Asn Phe Val Val Ser Thr Pro Gly Asn Asp  
 35 40 45

30

Ala Gln Gln Ala Gly Thr Gln Gln Gly Ala Asn Ser Lys Ser Val  
 50 55 60

35

Pro Glu Gln Gln Pro Gln Gln Ala Ala Gly Glu Thr Thr Ala Thr Val  
 65 70 75 80

40

Val Val Lys Thr Leu Asp Val Leu Arg Gly Glu Leu Arg Gly Gln Arg  
 85 90 95

45

Glu Ala Phe Leu Ser Glu Ile Ile Lys Ser Asp Gly Pro Phe Thr Ile  
 100 105 110

50

Leu Gln Leu Val Gly Tyr Leu Arg Val Val Asp Thr Asp Leu Leu Leu  
 115 120 125

55

Lys Val Asp Ser Thr Lys Val Asp Glu Ala Gly Lys Lys Val Lys Ala  
 130 135 140

**EP 1050 541 A1**

Tyr Leu Glu Lys Ile Gly Ile Arg Gly Asp Ser Val Glu Ala Ala Leu  
145 150 155 160

5

Asp Asn Leu Met Ile Lys Val Tyr Glu Ile Thr Lys Gly Thr Val Glu  
165 170 175

10

Ser Ser Ala Gln Gly Thr Asp Ser Glu Glu Leu Lys Thr Leu Leu Leu  
180 185 190

15

Lys Phe Ser Glu Asp Leu Lys Ala Glu Gln Glu Leu His Ser Glu Ala  
195 200 205

20

Lys Gly Gly Glu Ala Leu Leu Ser Ser Met Lys Thr Gln His Asp Glu  
210 215 220

25

Leu Leu Lys Phe Ala Ala Leu Thr Pro Thr Phe Leu Thr Ser Glu  
225 230 235 240

30

Asp Ile Ser Gly Tyr Leu Thr Val Pro Glu Tyr Gly Ala Pro Met Asn  
245 250 255

Ala Ala Lys Trp Lys Val Glu Gly Met Ile His Gly Lys Leu Glu  
260 265 270

35

Ser Ser Glu Val Pro Ala Asn Leu Lys Ala Leu Val Ala Glu Leu Ile  
275 280 285

40

Glu Leu Arg Glu Gln Met Met Asp Leu Leu Tyr Gly Pro Ile Gly His  
290 295 300

45

His Asp Cys Ala Ala Gly Ser Gly Gln Gly Ser Ser Pro Lys Lys Pro  
305 310 315 320

50

Ser Phe Ala Ala Val Pro Ser Ser Leu Ser Ala Ile Val Phe Gly Ile  
325 330 335

Ile Val Ser Met Phe  
340

55

5           <210> 3  
 <211> 1101  
 <212> DNA  
 <213> Babesia divergens  
  
 10          <220>  
 <221> CDS  
 <222> (76)..(1071)  
 15          <223> Weybridge  
  
 <400> 3  
 gaattcacga ccatacgaat aqttactgtt gtcgtttaac ttatataat cctaatacg 60  
 20  
 ttctctctaa ctacg atg aaa acc agt aag att ctc aac act gct gct atc 111  
 Met Lys Thr Ser Lys Ile Leu Asn Thr Ala Ala Ile  
 25                 1                         5                         10  
  
 tgc ctc ctg qct atg ggt ttc aat ggc aat aat gtg cgc tgc acc aat 159  
 Cys Leu Leu Ala Met Gly Phe Asn Gly Asn Asn Val Arg Cys Thr Asn  
 30                 15                         20                         25  
  
 ctc agt ggc gca cag cag cta gca gcg agt acc ccg ggt gtt tca act 207  
 35          Leu Ser Gly Ala Gln Gln Pro Ala Ala Ser Thr Pro Gly Val Ser Thr  
 30                 35                         40  
  
 tct gga aat gat tcc cag caa ggt atc act tca gag cag cca cag 255  
 40          Ser Gly Asn Asp Ser Gln Gln Gly Ile Thr Ser Glu Gln Gln Pro Gln  
 45                 50                         55                         60  
  
 cag gct gcc ggc gaa acc cct gct aag gtc gtg gta aag act cta gat 303  
 45          Gln Ala Ala Gly Glu Thr Pro Ala Lys Val Val Val Lys Thr Leu Asp  
 65                 70                         75  
  
 50          gaa ctc cgt ggg gaa ctc agg ggg cag cgt gag gct ttc ctt tca gag 351  
 Glu Leu Arg Gly Glu Leu Arg Gly Gln Arg Glu Ala Phe Leu Ser Glu

55

**EP 1 050 541 A1**

	80	85	90	
5	ata att aad tcc gat qqt cca ttc act att ttg caq ttg qtt ggc tac			399
	Ile Ile Lys Ser Asp Gly Pro Phe Thr Ile Leu Gln Leu Val Gly Tyr			
	95	100	105	
10	ctt cgt gtt atc gac aca gat ctt ctc ctg aag gtt gat tcc gtg aag			447
	Leu Arg Val Ile Asp Thr Asp Leu Leu Leu Lys Val Asp Ser Val Lys			
	110	115	120	
15	gtt act gaa gcc ggc aag aag gtc aag acc tac ctt gaa aaa att gga			495
	Val Thr Glu Ala Gly Lys Lys Val Lys Thr Tyr Leu Glu Lys Ile Gly			
	125	130	135	140
20	ata acg ggt gac agt gtt gag gca gca ctt gac aat ctt atg ata aag			543
	Ile Thr Gly Asp Ser Val Glu Ala Ala Leu Asp Asn Leu Met Ile Lys			
	145	150	155	
25	att tat gaa ctc acc aat ggt act gtg gaa agt tca cca caa ggt act			591
	Ile Tyr Glu Leu Thr Asn Gly Thr Val Glu Ser Ser Pro Gln Gly Thr			
	160	165	170	
30	gac agt gag gag ctg aag act ttg tta aag ttc agg gag gat ctc			639
	Asp Ser Glu Glu Leu Lys Thr Leu Leu Leu Lys Phe Arg Glu Asp Leu			
	175	180	185	
35	agg gct gag caa gaa ctt tat agt gaa gcc aag ggc ggt gag gac ttg			687
	Arg Ala Glu Gln Glu Leu His Ser Glu Ala Lys Gly Glu Ala Leu			
	190	195	200	
40	ctt tct agc atg aag aag tag cat gac gaa cta ctt aag aag ttt gct			735
	Leu Ser Ser Met Lys Thr Gln His Asp Glu Leu Leu Lys Lys Phe Ala			
	205	210	215	220
45	gcc ctt aac cct act ttc tta tcc aca gag gat ata tct ggc tac ctt			783
	Ala Leu Asn Pro Thr Phe Leu Ser Thr Glu Asp Ile Ser Gly Tyr Leu			
	225	230	235	
50				
55				

## EP 1050 541 A1

acc gtg ccc gaa tac ggt gcc ccc atg aat gct gcg aag tgg aaa aag 831  
 Thr Val Pro Glu Tyr Gly Ala Pro Met Asn Ala Ala Lys Trp Lys Lys  
 5 240 245 250

gtc gaa gga aag atc aat gaa aag ttc gag tct tcc gaa ata caa ggt 874  
 Val Glu Gly Lys Ile Asn Glu Lys Leu Glu Ser Ser Glu Ile Gln Gly  
 10 255 260 265

gat ctc aaa gct ttg gtt gca gag tta att aag ttc cgt gac cag atg 927  
 Asp Leu Lys Ala Leu Val Ala Glu Leu Ile Lys Leu Arg Glu Gln Met  
 15 270 275 280

atg gat ttg cta tac ggc cct att ggt cat cac gat tgt gct gca gga 975  
 Met Asp Ile Leu Tyr Gly Pro Ile Gly His His Asp Cys Ala Ala Gly  
 20 295 290 295 300

tca ggt cag gga tct agt cct aag aag cca tcc ttc gct gct gta cct 1023  
 Ser Gly Gln Gly Ser Ser Pro Lys Lys Pro Ser Phe Ala Ala Val Pro  
 25 305 310 315

tct tct ttg tgt gtc att gtc ttc ggt atc att gtc tca atg ttc taa 1071  
 Ser Ser Ile Cys Ala Ile Val Phe Gly Ile Ile Val Ser Met Phe  
 30 320 325 330

35 gtggacatgt atgtatgtt tggatgtgt 1101

<210> 4  
 40 <211> 331  
 <212> PRT  
 <213> Babesia divergens

45 <400> 4  
 Met Lys Thr Ser Lys Ile Leu Asn Thr Ala Ala Ile Cys Leu Leu Ala  
 1 5 10 15

50 Met Gly Phe Asn Gly Asn Asn Val Arg Cys Thr Asn Leu Ser Gly Ala  
 20 25 30

55

**EP 1050 541 A1**

Gln Gln Pro Ala Ala Ser Thr Phe Gly Val Ser Thr Ser Gly Asn Asp  
35 40 45

5

Ser Gln Gln Gly Ile Thr Ser Glu Gln Gln Pro Gln Gln Ala Ala Gly  
50 55 60

10

Glu Thr Pro Ala Lys Val Val Val Lys Thr Leu Asp Glu Leu Arg Gly  
65 70 75 80

15

Glu Leu Arg Gly Gln Arg Glu Ala Phe Leu Ser Glu Ile Ile Lys Ser  
85 90 95

20

Asp Gly Pro Phe Thr Ile Leu Gln Leu Val Gly Tyr Leu Arg Val Ile  
100 105 110

25

Asp Thr Asp Leu Leu Lys Val Asp Ser Val Lys Val Thr Glu Ala  
115 120 125

30

Gly Lys Lys Val Lys Thr Tyr Leu Glu Lys Ile Gly Ile Thr Gly Asp  
130 135 140

35

Ser Val Glu Ala Ala Leu Asp Asn Leu Met Ile Lys Ile Tyr Glu Leu  
145 150 155 160

40

Thr Asn Gly Thr Val Glu Ser Ser Pro Gin Gly Thr Asp Ser Glu Glu  
165 170 175

45

Leu Lys Thr Leu Leu Lys Phe Arg Glu Asp Leu Arg Ala Glu Gln  
180 185 190

Lys Thr Gln His Asp Glu Leu Leu Lys Phe Ala Ala Leu Asn Pro  
210 215 220

50

Thr Phe Leu Ser Thr Glu Asp Ile Ser Gly Tyr Leu Thr Val Pro Glu

**EP 1050 541 A1**

225                    230                    235                    240  
5      Tyr Gly Ala Pro Met Asn Ala Ala Lys Thr Lys Lys Val Glu Gly Lys  
                      245                        250                        255  
  
10     Ile Asn Glu Lys Leu Glu Ser Ser Glu Ile Gln Gly Asp Leu Lys Ala  
                      260                        265                        270  
  
15     Leu Val Ala Glu Leu Ile Lys Leu Arg Glu Gln Met Met Asp Leu Leu  
                      275                        280                        285  
  
20     Tyr Gly Pro Ile Gly His His Asp Cys Ala Ala Gly Ser Gly Gln Gly  
                      290                        295                        300  
25     Ser Ser Pro Lys Lys Pro Ser Phe Ala Ala Val Pro Ser Ser Leu Cys  
                      305                        310                        315                        320  
30     Ala Ile Val Phe Gly Ile Ile Val Ser Met Phe  
                      325                        330  
  
35     <210> 5  
                      <211> 1033  
                      <212> DNA  
                      <213> Babesia divergens  
  
40     <220>  
                      <221> cDS  
                      <222> (20)..(100)  
                      <223> rS  
  
45     <400> 5  
caaggatcct ctaagtacg atg aaa acc agt aaa att ctc aac acg gct gct 52  
                      Met Lys Thr Ser Lys Ile Leu Asn Thr Ala Ala  
50     1                        5                                10  
  
                      atc tgc ctc ctg gct atg ggt ttc aat ggc aat aat gtg agc tgc gcc 100  
55

**EP 1050 541 A1**

Ile Cys Leu Leu Ala Met Gly Phe Asn Gly Asn Asn Val Ser Cys Ala  
15 20 25

5

Cat Atc Agt Ggc Aca Cag Gag Aca Gca Gcg Gtt Aac Tcg Ggt Gac Tca 148  
His Ile Ser Gly Thr Gln Glu Thr Ala Ala Ala Asn Ser Gly Asp Ser  
10 30 35 40

10

Act Act Agg Aat Gac Gcg Cag Cag Tct Ggt Gaa Gta Cag Caa Act Cca 196  
Thr Thr Arg Asn Asp Ala Gln Gln Ser Gly Glu Val Gln Gln Thr Pro  
15 45 50 55

15

Cag Cag Acc Cct Gta Aag Gct Gta Gta Aaa Tcc Ctg Gag Gac Tta Cgt 244  
Gln Gln Thr Pro Val Lys Ala Val Val Lys Ser Leu Glu Asp Leu Arg  
20 60 65 70 75

20

Gaa Gag Ctt Aag Ggt Cag Cgt Gaa Acc Ttc Ctt Tca Aag Tta Att Gag 292  
Glu Glu Leu Lys Gly Gln Arg Glu Thr Phe Leu Ser Lys Leu Ile Glu  
25 80 85 90

25

Tcg Gac Gga Gca Ttc Ggt Ttt Ctt Caa Ttg Atc Gac Ttc Ctt Cgt Gtt 340  
Ser Asp Gly Ala Phe Gly Phe Leu Gln Leu Ile Asp Phe Leu Arg Val  
30 95 100 105

30

Att Gac Aca Gac Ctt Ctc Ctg Aag Gtt Gac Ggg Aca Aag Gtt Gag Aaa 388  
Ile Asp Thr Asp Leu Leu Leu Lys Val Asp Gly Thr Lys Val Glu Lys  
35 110 115 120

35

Gcc Gga Gtt Aaa Gtg Aag Gcc Tac Ctt Gag Tct Att Gga Ata Aag Ggt 436  
Ala Gly Val Lys Val Lys Ala Tyr Leu Glu Ser Ile Gly Ile Lys Gly  
40 125 130 135

40

Gga Agt Gtt Gag Gaa Tgt Ctt Gac Aat Ctt Atg Aca Aag Gtt Tct Gca 484  
Gly Ser Val Glu Glu Cys Leu Asp Asn Leu Met Thr Lys Val Ser Ala  
45 140 145 150 155

45

Atc Acc Agg Ggt Act Gta Gaa Ggt Tca Gca Caa Agt Act Gac Agt Gag 532  
Ile Thr Arg Gly Thr Val Glu Gly Ser Ala Gln Ser Thr Asp Ser Glu  
50 160 165 170

55

## EP 1050 541 A1

	gat ctg aag act ttg tta cta aag ttc agc gaa gat ctc aag gct gag	580
	Asp Leu Lys Thr Leu Leu Leu Lys Phe Ser Glu Asp Leu Lys Ala Glu	
5	175	180
	185	
	caa gaa cgc cat ggt gac aag gat gaa aat aag gaa tta ctg aag aat	628
	Gln Glu Arg His Gly Asp Lys Asp Glu Ser Lys Glu Leu Leu Lys Asn	
10	190	195
	200	
	ttg ggt gtg cag cgt gat gaa ttg gtc aag aag ttt act gag atg agc	676
	Leu Gly Val Gln Arg Asp Glu Leu Val Lys Lys Phe Thr Glu Met Ser	
15	205	210
	215	
	cca tcc ttc ttg acc tca gaa gat ata tat ggc ttc ctc acg gtg ccg	724
	Pro Ser Phe Leu Thr Ser Glu Asp Ile Ser Gly Phe Leu Thr Val Pro	
20	220	225
	230	235
	gag tac ggt ttc cct atg gat gct gct aag aag gtc gaa aag	772
	Glu Tyr Gly Phe Pro Met Asp Ala Ala Lys Trp Lys Lys Val Glu Lys	
25	240	245
	250	
	aag atc aat gat aag tcc gag tat tcc gat ata aca act gac ctc aaa	820
	Lys Ile Ser Asp Lys Leu Glu Ser Ser Asp Ile Thr Thr Asp Leu Lys	
30	255	260
	265	
	act ctg ctt gca aag ttg att gaa cag cgt gaa aaa atg atg gat ttg	868
	Thr Leu Leu Ala Lys Leu Ile Glu Gln Arg Glu Lys Met Met Asp Leu	
35	270	275
	280	
	cta tac ggc cct att ggt cat gag gat tgt cct gcc aga tca ggt cag	916
	Leu Tyr Gly Pro Ile Gly His Glu Asp Cys Pro Ala Arg Ser Gly Gln	
40	285	290
	295	
	gga tct ggt ccg aag aag cca tcc ttc gca gct gtg ccc tcc tct tlg	964
	Gly Ser Gly Pro Lys Lys Pro Ser Phe Ala Ala Val Pro Ser Ser Leu	
45	300	305
	310	315
	tgc gcc att gtg ttc ggt atc att gta tca atg ttc taa gtggacaaqct	1013
50		
55		

EP 1050 541 A1

Cys Ala Ile Val Phe Gly Ile Val Ser Met Phe

320

325

5

atgttagcttt tggatccgt

1033

10

<210> 6

<211> 327

<212> PRT

15

<213> Babesia divergens

<400> 6

Met Lys Thr Ser Lys Ile Leu Asn Thr Ala Ala Ile Cys Leu Leu Ala

20

5

10

15

Met Gly Phe Asn Gly Asn Asn Val Ser Cys Ala His Ile Ser Gly Thr

20

25

30

25

Gln Glu Thr Ala Ala Asn Ser Gly Asp Ser Thr Thr Arg Asn Asp

35

40

45

30

Ala Gln Gln Ser Gly Glu Val Gln Gln Thr Pro Gln Gln Thr Pro Val

50

55

60

35

Lys Ala Val Val Lys Ser Leu Glu Asp Leu Arg Glu Glu Leu Lys Gly

65

70

75

80

40

Gln Arg Glu Thr Phe Leu Ser Lys Leu Ile Glu Ser Asp Gly Ala Phe

85

90

95

40

Gly Phe Leu Gln Leu Ile Asp Phe Leu Arg Val Ile Asp Thr Asp Leu

100

105

110

45

Leu Leu Lys Val Asp Gly Thr Lys Val Glu Lys Ala Gly Val Lys Val

115

120

125

50

Lys Ala Tyr Leu Glu Ser Ile Gly Ile Lys Gly Gly Ser Val Glu Glu

130

135

140

55

**EP 1050 541 A1**

Cys Leu Asp Asn Leu Met Thr Lys Val Ser Ala Ile Thr Arg Gly Thr  
145 150 155 160  
5 Val Glu Gly Ser Ala Gln Ser Thr Asp Ser Glu Asp Leu Lys Thr Leu  
165 170 175  
10 Leu Leu Lys Phe Ser Glu Asp Leu Lys Ala Glu Gln Glu Arg His Gly  
180 185 190  
15 Asp Lys Asp Glu Ser Lys Glu Leu Leu Lys Asn Leu Gly Val Gln Arg  
195 200 205  
20 Asp Glu Leu Val Lys Phe Thr Glu Met Ser Pro Ser Phe Leu Thr  
210 215 220  
25 Ser Glu Asp Ile Ser Gly Phe Leu Thr Val Pro Glu Tyr Gly Phe Pro  
225 230 235 240  
30 Met Asp Ala Ala Lys Trp Lys Val Glu Lys Lys Ile Ser Asp Lys  
245 250 255  
35 Leu Glu Ser Ser Asp Ile Thr Asp Leu Lys Thr Leu Leu Ala Lys  
260 265 270  
40 Leu Ile Glu Gln Arg Glu Lys Met Met Asp Leu Leu Tyr Gly Pro Ile  
275 280 285  
45 Gly His Glu Asp Cys Pro Ala Arg Ser Gly Gln Gly Ser Gly Pro Lys  
290 295 300  
50 Lys Pro Ser Phe Ala Ala Val Pro Ser Ser Leu Cys Ala Ile Val Phe  
305 310 315 320  
55 Gly Ile Ile Val Ser Met Phe  
325

5 <210> 7  
<211> 21  
<212> DNA  
<213> Babesia divergens

10 <220>  
<221> misc\_feature  
<222> (1)..(21)  
<223> PRIMER Bd37-S

15 <400> 7  
qaattcacga ccatacqaat a 21

20  
25 <210> 8  
<211> 21  
<212> DNA  
<213> Babesia divergens

30 <220>  
<221> misc\_feature  
<222> (1)..(21)  
<223> PRIMER Bd37-E1

35 <400> 8  
caagggtggtg cgtttttttttt g 21

40  
45 <210> 9  
<211> 24  
<212> DNA  
<213> Babesia divergens

50 <220>  
<221> misc\_feature  
<222> (1)..(24)  
<223> PRIMER Bd37-E4

5 <400> 9  
atacaatgtat accgaattca atgg  
10 <210> 10  
<211> 31  
<212> DNA  
<213> Babesia divergens  
15 <220>  
<221> misc\_feature  
<222> (1)..(31)  
20 <223> PRIMER Bd37-low  
  
<400> 10  
acaggatcca aaagctacat aqctqtccac t  
25  
26  
27  
28  
29  
30 <210> 11  
<211> 33  
<212> DNA  
<213> Babesia divergens  
35 <220>  
<221> misc\_feature  
<222> (1)..(33)  
40 <223> PRIMER Bd37-Upp  
  
<400> 11  
caaggatcct ctaagtatga tgaaaaccag taa  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2049  
2050  
2051  
2052  
2053  
205

## **Claims**

50 1. Nucleic acid sequence of *Babesia divergens* characterised in that it encodes a protein of the 37 kD protein family or an immunogenic fragment thereof.

55 2. Nucleic acid sequence according to claim 1, characterised in that the protein has a molecular weight of 37 kD.

3. Nucleic acid sequence according to claim 1, characterised in that the protein has a molecular weight of 35 kD.

4. Nucleic acid sequence according to claim 2, characterised in that it comprises the sequence shown in SEQ ID NO

1.

5. Nucleic acid sequence according to claim 3, characterised in that it comprises the sequence shown in SEQ ID NO 2 or 3.

5

6. Nucleic acid sequence encoding a protein of the 37 kD protein family that is capable of binding to the monoclonal antibody F42F8.

10

7. Recombinant DNA molecule characterised in that it comprises a nucleic acid sequence according to claims 1-6 and regulating sequences enabling expression of said nucleic acid sequence.

15

8. Live recombinant carrier micro-organism comprising a nucleic acid sequence according to claims 1-7.

9. Live recombinant carrier according to claim 8, characterised in that said carrier additionally comprises a heterologous gene encoding an antigen of a cattle-pathogen, which is able to elicit an immune response.

20

10. Live recombinant carrier according to claim 9, characterised in that said cattle pathogen is selected from the group of cattle pathogens, consisting of Bovine Herpesvirus, bovine Viral Diarrhoea virus, Parainfluenza type 3 virus, Bovine Paramyxovirus, Foot and Mouth Disease virus, *Pasteurella haemolytica*, Bovine Respiratory Syncytial Virus, *Theileria parva*, *Theileria annulata*, *Babesia bovis*, *Babesia bigemina*, *Babesia major*, *Trypanosoma species*, *Anaplasma marginale*, *Anaplasma centrale* or *Neospora caninum*.

25

11. Host cell comprising a nucleic acid sequence according to claims 1-6, a recombinant DNA molecule according to claim 7 or a live recombinant carrier according to claims 8-10.

12. Vaccine inducing protection against infection of cattle with *B. divergens* or the clinical manifestations of the infection, characterised in that it comprises at least one protein of the 37 kD protein family or an immunogenic fragment thereof and a pharmaceutically acceptable carrier.

30

13. Vaccine according to claim 12, characterised in that it comprises two or more different proteins of the 37 kD protein family.

14. Vaccine according to claim 13, characterised in that it comprises 50-75% of a 37 kD member of the 37 kD protein family and 50-25% of a 35 kD protein member of the 37 kD protein family.

35

15. Vaccine inducing protection against infection of cattle with *B. divergens* or the clinical manifestations of the infection, characterised in that it comprises a nucleic acid sequence according to claims 1-6, a recombinant DNA molecule according to claim 7, a live recombinant carrier according to claims 8-10 or a host cell according to claim 11.

40

16. Vaccine protecting against infection of cattle with *B. divergens* or the clinical manifestations of the infection, characterised in that it comprises antibodies against a protein of the 37 kD family.

17. Method for the preparation of a vaccine according to claim 12, 15 or 16, characterised in that said method comprises the admixing of a protein of the 37 kD protein family or an immunogenic fragment thereof, antibodies against a protein of the 37 kD family, a nucleic acid sequence according to claims 1-6, a recombinant DNA molecule according to claim 7, a live recombinant carrier according to claims 8-10 or a host cell according to claim 11 and a pharmaceutically acceptable carrier.

45

18. Method for the preparation of a vaccine according to claim 13, characterised in that said method comprises the admixing of two different proteins of the 37 kD protein family or immunogenic fragments thereof and a pharmaceutically acceptable carrier.

50

19. Diagnostic kit for the detection of antibodies against *Babesia divergens*, said kit comprising purified protein of the 37 kD protein family or fragments thereof still comprising an antigenic determinant.

55

20. Diagnostic kit for the detection of *Babesia divergens*, said kit comprising antibodies reactive with an antigenic determinant on a protein the 37 kD protein family.

21. Method for the detection of antibodies against *Babesia divergens*, said method comprising incubating serum with a protein of the 37 kD protein family or an antigenic fragment thereof.
- 5      22. Method for the detection of *Babesia divergens* parasites, said method comprising incubating serum with antibodies against a protein of the 37 kD protein family.
23. Use of a protein of the 37 kD protein family or a mixture of such proteins for the manufacture of a vaccine inducing protection against infection of cattle with *B. divergens* or the clinical manifestations of the infection

**10**

**15**

**20**

**25**

**30**

**35**

**40**

**45**

**50**

**55**

Fig. 1 :

	10	20	30	40	50	
60						
1	<b>GAATTACGACCATACTGAATAGTTACTGTTGTCGGTTAACTTATTAAATATCCTAATCAAG</b>					
2	<b>GAATTACGACCATACTGAATAGTTACTGTTGTCGGTTAACTTATTAAATATCCTAATCAAG</b>					
3	<b>-----CAAG</b>					
	*****					
120	70	80	90	100	110	
1	<b>TTCTTTCTAAGTACGATGAAAACCAGTAAGATTCTAACACTGCTGCTATCTGCCTCTG</b>					
2	<b>TTCTCTCTAACTACGATGAAAACCAGTAAGATTCTAACACTGCTGCTATCTGCCTCTG</b>					
3	<b>GATCCTCTAAGTACGATGAAAACCAGTAAAATTCTAACACACGGCTGCTATCTGCCTCTG</b>					
	*****					
180	130	140	150	160	170	180
1	<b>GCTATGGGTTCAATGGCAATAATGTGAGCTGCACCAATCTCAATGGCTCACAGGAGCCA</b>					
2	<b>GCTATGGGTTCAATGGCAATAATGTGCGCTGCACCAATCTCAGTGGCGCACAGCAGCCA</b>					
3	<b>GCTATGGGTTCAATGGCAATAATGTGAGCTGCAGCCCATATCAGTGGCACACAGGAGACA</b>					
	*****					*****
240	190	200	210	220	230	240
1	<b>GCACGGCTAACCTGTTGTTCAACTCTGGAAATGATGCGCAGCAGGCTGGTACGGAG</b>					
2	<b>GCAGCGAGTACCCCCGGGTGTTCAACTCTGGAAATGATTGCGCAGCAAGGTATCA</b>					
3	<b>GCACGGCTAACCTGGGTGATTCAACTACTAGGAATGATGCGCAGCAGTCTGGTGA</b>					
	*****					*
300	250	260	270	280	290	300
1	<b>CAAGGTGGTGCAGACTCAAAGTCCGTCCAGAGCAGCAG</b>					
2	<b>-----CTTCAGAGCAGCAG</b>					
3	<b>-----AGTACAGCAAATCCACAGCAG</b>					
	**					*****

EP 1 050 541 A1

	310	320	330	340	350	360
1						
2	GAAACCACGTACGGTCGTGGTAAAGACTCTAGATGTGCTCCGTGGGAACTCAGGGGG					
3	GAAACCCCTGCTAAGGTCGTGGTAAAGACTCTAGATGAACTCCGTGGGAACTCAGGGGG					
	---ACCCCTGTAAGGCTGTAGTAAAATCCCTGGAGGATTACGTGAAGAGCTTAAGGGT					
	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *
	370	380	390	400	410	420
1						
2	CAGCGTGAGGCTTCCTTCAGAGATAATTAAATCGGATGGTCATTCACTATTTGCAG					
3	CAGCGTGAGGCTTCCTTCAGAGATAATTAAATCGGATGGTCATTCACTATTTGCAG					
	CAGCGTGAACCTTCCTTCAGAGTTAATTGAGTCGGATGGAGCATTGGTTTCTTCAG					
	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *
	430	440	450	460	470	480
1						
2	TTGGTTGGCTACCTTCGTGTTGTCGACACAGATCTCTCCTGAAAGTTGATCCACGAAG					
3	TTGGTTGGCTACCTTCGTGTTATGACACAGATCTCTCCTGAAAGTTGATCCGTGAAG					
	TTGATCGATTCCTTCGTGTTATGACACAGATCTCTCCTGAAAGTTGACCGGACAAAG					
	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *
	490	500	510	520	530	540
1						
2	GTTGATGAAGCCGGCAAGAAGGTCAAGGCCTACCTGAAAAAATTGGAATAAGGGGTGAC					
3	GTTACTGAAGCCGGCAAGAAGGTCAAGACCTACCTGAAAAAATTGGAATAACGGGTGAC					
	GTTGAGAAAGCGGGAGTTAAAGTGAAGGCCTACCTGAGTCTATTGGAATAAGGGTGGAA					
	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *
	550	560	570	580	590	600
1						
2	AGTGGTTGAGCAGCGCTTGACAATCTTATGATAAAGGTTATGAAATCACCAAAGGTACT					
3	AGTGGTTGAGGCAGCACTTGACAATCTTATGATAAAGGTTATGAACTCACCAAATGGTACT					
	AGTGGTTGAGGAATGTCTTGACAATCTTATGACAAAGGTTCTGCAATCACCAGGGGTACT					
	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *	* * * * *
	610	620	630	640	650	660
1						
2	GTGGAAAGTTCAGCACAAAGTACTGACAGTGAGGGAGCTGAAGACTTTGTTATTAAAGTTCA					
3	GTGGAAAGTTCAGCACAAAGTACTGACAGTGAGGGAGCTGAAGACTTTGTTATTAAAGTTCA					
	GTAGAAGGTTCAGCACAAAGTACTGACAGTGAGGGAGCTGAAGACTTTGTTACTAAAGTTCA					

EP 1 050 541 A1

\*\*\*\*\*  
670        680        690        700        710        720  
|            |            |            |            |            |  
1 AGCGAAGATCTCAAGGCTGAGCAAGAACCTCATAGTGAAGCCAAGGGCG---GTGAGGCC  
2 AGGGAGGATCTCAGGGCTGAGCAAGAACCTCATAGTGAAGCCAAGGGCG---GTGAGGCC  
3 AGCGAAGATCTCAAGGCTGAGCAAGAACGCCATGGTA---CAAGGATGAAAGTAGAAGGAA  
\*\*\*\*\*  
730        740        750        760        770        780  
|            |            |            |            |            |  
1 TTGCTTTCTAGCATGAAGACGCAGCATGATGAACTACTTAAGAACGTTGCTGCCCTTACC  
2 TTGCTTTCTAGCATGAAGACGCAGCATGACGAACACTTAAGAACGTTGCTGCCCTAAC  
3 TTACTGAAGAATTGGGTGTGCAGCGTGATGAATTGGTCAAGAACGTTACTGAGATGAGC  
\*\*\*\*\*  
790        800        810        820        830        840  
|            |            |            |            |            |  
1 CCTACTTTCTAACCTCAGAGGATATATCTGGCTACCTTACCGTGCCGGAATACGGTGCC  
2 CCTACTTTCTTATCCACAGAGGATATATCTGGCTACCTTACCGTGCCGGAATACGGTGCC  
3 CCATCCTTCTTGACCTCAGAAGATATATCTGGCTTCACGGTGCCGGAGTACGGTTTC  
\*\*\*\*\*  
850        860        870        880        890        900  
|            |            |            |            |            |  
1 CCTATGAATGCTGCGAAGTGGAAAAAGGTGGAAGGAATGATCCATGGAAAGCTCGAGTCT  
2 CCTATGAATGCTGCGAAGTGGAAAAAGGTGGAAGGAAGATCAATGAAAAGCTCGAGTCT  
3 CCTATGGATGCTGCTAAGTGGAAAGAAGTGGAAAAGAACGATCAGTGATAAGCTCGAGTCT  
\*\*\*\*\*  
910        920        930        940        950        960  
|            |            |            |            |            |  
1 TCCGAAAGTACCAAGCTAATCTCAAAGCTCTGGTTGCAGAGTTAATTGAGTTGCGTGAACAG  
2 TCCGAAATACAAGGTGATCTCAAAGCTCTGGTTGCAGAGTTAATTGAGTTGCGTGAACAG  
3 TCCGATATAACAAACTGACCTCAAAACTCTGTTGCAAAGTGTATTGAAACAGCGTGAAAAA  
\*\*\*\*\*  
970        980        990        1000        1010  
|            |            |            |            |  
1020

1 ATGATGGATTTGCTATA CGGCCCTATTGGTCATCACGATTGTGCTGCAGGATCAGGTCA  
2 ATGATGGATTTGCTATA CGGCCCTATTGGTCATCACGATTGTGCTCCAGGATCAGGTCA  
3 ATGATGGATTTGCTATA CGGCCCTATTGGTCATGAGGATTGTCCAGATCAGGTCA  
\*\*\*\*\*

1030 1040 1050 1060 1070 1080  
| | | | | |  
1 GGATCTAGTCCTAAGAACCGATCCTCGCTGCTGTACCTTCTTCTTGTCTGCCATTGTC  
2 GGATCTAGTCCTAAGAACCGATCCTCGCTGCTGTACCTTCTTCTTGTGTGCCATTGTC  
3 GGATCTGGTCCGAAGAACCGATCCTCGCAGCTGTGCCCTCCTTTGTGCGCCATTGTC  
\*\*\*\*\*

1090 1100 1110 1120 1130 1137  
| | | | | |  
1 TTCGGTATCATTGTATCAATGTTCTAAGTGGACAGCTATGTAGCTTTGGATCCTGT  
2 TTCGGTATCATTGTGTCAATGTTCTAAGTGGACAGCTATGTAGCTTTGGATCCTGT  
3 TTCGGTATCATTGTATCAATGTTCTAAGTGGACAGCTATGTAGCTTTGGATCCTGT  
\*\*\*\*\*

1 Rouen 1987  
2 Weybridge 5843  
I.O.W.  
3 Y5

Fig. 2 :

4 PIGHHDCAAGSGQGSSPKKPSFAAVPSSL S A I V F G I I V S M F  
5 PIGHHDCAAGSGQGSSPKKPSFAAVPSSL C A I V F G I I V S M F  
6 PIGHEDCPARSGQGSGPKKPSFAAVPSSL C A I V F G I I V S M F  
\*\*\*\*\*. \* \* \* \* \* . \*

4: Strain Rouen 1987      341 aa  
5: Strain Weybridge      331 aa  
6: Strain Y5      327 aa

# BEST AVAILABLE COPY

EP 1 050 541 A1






Fig.3

**BEST AVAILABLE COPY**

EP 1 050 541 A1



2A : serum collected at day-22



2B : serum collected at day-1

**Fig. 4**




Figure 5



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number

EP 00 20 1485

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	EP 0 417 524 A (COMMW SCIENT IND RES ORG) 20 March 1991 (1991-03-20) * abstract * * page 10, column 17, line 22 - page 16, column 30, line 41 * ---	1-10	C07K14/44 A61K39/018 C12N15/00 C07K16/20 G01N33/53
Y	GRANDE N. ET AL.: "Comparison between aseric and seric culture-derived exoantigens of Babesia divergens in their ability to induce immunoprotection in gerbils" PARASITOLOGY INTERNATIONAL, vol. 47, no. 4, December 1998 (1998-12), pages 269-279, XP002116986 * the whole document *	1-10	
A	CARCY B. ET AL.: "A 37-kilodalton glycoprotein of Babesia divergens is a major component of a protective fraction containing low-molecular-mass culture-derived exoantigens" INFECTION AND IMMUNITY, vol. 63, no. 3, 1995, pages 811-817, XP002116987 WASHINGTON US * the whole document *	1-10	
A	D'OLIVEIRA C ET AL: "Expression of genes encoding two major Theileria annulata merozoite surface antigens in Escherichia coli and a Salmonella typhimurium aroA vaccine strain" GENE, vol. 172, no. 1, 12 June 1996 (1996-06-12), page 33-39 XP004042704 ISSN: 0378-1119 * the whole document *	10	A61K C07K
		-/-	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
BERLIN	13 July 2000	Panzica, G	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent  
Office

## **EUROPEAN SEARCH REPORT**

**Application Number**

EP 00 20 1485

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	<p>EP 0 834 567 A (CORIXA CORP) 8 April 1998 (1998-04-08)</p> <p>-----</p>		
			<p><b>TECHNICAL FIELDS SEARCHED</b> (Int.Cl.7)</p>
<p>The present search report has been drawn up for all claims</p>			
Place of search	Date of completion of the search	Examiner	
BERLIN	13 July 2000	Panzica, G	
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone            Y : particularly relevant if combined with another document of the same category            A : technological background            O : non-written disclosure            P : intermediate document</p>		<p>T : theory or principle underlying the invention            E : earlier patent document, but published on, or after the filing date            D : document cited in the application            L : document cited for other reasons            .....            &amp; : member of the same patent family, corresponding document</p>	

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 20 1485

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

13-07-2000

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0417524	A	20-03-1991	AT	122096 T	15-05-1995
			AU	640398 B	26-08-1993
			AU	6124690 A	28-02-1991
			DE	69019092 D	08-06-1995
			ZA	9006667 A	26-06-1991
EP 0834567	A	08-04-1998	NONE		

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82